PCT



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 3: C12N 15/00, 5/00; C12P 21/00 A01B 79/00

A1

(11) International Publication Number:

WO 84/ 02920

(43) International Publication Date:

2 August 1984 (02.08.84)

(21) International Application Number: PCT/US84/00050

(22) International Filing Date:

16 January 1984 (16.01.84)

(31) Priority Application Number:

458,402

(32) Priority Date:

17 January 1983 (17.01.83)

(33) Priority Country:

US

(71) Applicant: MONSANTO COMPANY [US/US]; 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US).

(72) Inventors: FRALEY, Robert, Thomas; 828 Lisakay Drive, Glendale, MO 63167 (US). HORSCH, Robert, Bruce; 12316 Tempo Drive, St. Louis, MO 63141 (US). ROGERS, Stephen, Gary; 312 Sylvester Avenue, Webster Groves, MO 63119 (US).

(74) Agent: BRUSOK, Fabian, A.; 800 North Lindbergh Boulevard, St. Louis, MO 63167 (US). (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published ·

With international search report.

0) 292(

0.84

7.1.74 (1) (3) (3)(4)

(54) Title: GENETICALLY TRANSFORMED PLANTS

(57) Abstract

Genetically transformed, non-tumorous plant cells. A modified Ti plasmid is created which contains a left T-DNA border, one or more desired genes, and a right T-DNA border. This region does not contain tumorigenic or phytohormone-altering genes. The Ti plasmid is inserted into plant cells, where the T-DNA region is transferred into the plant genome. The transformed plant cells may be regenerated into morphologically normal plants which will pass the desired gene(s) to their descendants.

SELECT PLASMID HAVING T-DNA BORDER, A.TUM. MARKER, PLANT CELL MARKER, UNIQUE CLEAVAGE SITE, AND TI HOMOLOGY INSERT DESIRED GENE INTO PLASMID. INSERT PLASMID INTO A.TUM. CELL HAVING TI PLASMID; CULTIVATE TO 292(ALLOW CROSSOVER EVENT SELECT A. TUM. CELLS HAVING CO-INTEGRATE PLASMIDS ٠, .: INSERT CO-INTEGRATE CO-CULTIVATE A. TUM. CELLS WITH PLANT PLASMIDS INTO SELECT TRANSFORMED PLANT CELLS HAVING PLANT CELL MARKER ű, REGENERATE PLANTS FROM TRANSFORMED PLANT CELLS 2920

•

GENETICALLY TRANSFORMED PLANTS

Technical Field

This invention is in the fields of genetic engineering, plant biology, and bacteriology.

BACKGROUND ART

In the past decade, the science of genetic 10 engineering has developed rapidly. A variety of processes are known for inserting a heterologous gene into bacteria, whereby the bacteria become capable of efficient expression of the inserted genes. Such processes normally involve the use of 15 plasmids which may be cleaved at one or more selected cleavage sites by restriction endonucleases. Typically, a gene of interest is obtained by cleaving one piece of DNA, and the resulting DNA fragment is mixed with a fragment 20 obtained by cleaving a vector such as a plasmid. The different strands of DNA are then connected ("ligated") to each other to form a reconstituted plasmid. See, for example, U.S. Patents 4,237,224 (Cohen and Boyer, 1980); 4,264,731 25 (Shine, 1981); 4,273,875 (Manis, 1981); 4,322,499 (Baxter et al, 1982), and 4,336,336 (Silhavy et al, 1982).



A variety of other reference works are available. Some of these works describe the natural process whereby DNA is transcribed into mRNA and mRNA is translated into protein, see, 5 e.g., L. Stryer, Biochemistry, 2nd edition, p 559 et seq. (W. H. Freeman and Co., 1981); A. L. Lehninger, Biochemistry, 2nd edition, p. 853 et seq. (Worth Publ., 1975). Other works describe methods and products of genetic manipulation; see, e.g., T. Maniatis et al, Molecular Cloning, A 10 Laboratory Manual (Cold Spring Harbor Labs, 1982); J.K. Setlow and A. Hollaender, Genetic Engineering, Principles and Methods (Plenum Press, 1979). Hereafter, all references will be cited in abbreviated form; a list of complete citations is 15 included after the Examples.

performed to date involves the insertion of genes into various types of cells, primarily bacteria such as <u>E. coli</u>, various other microorganisms such as yeast, and mammalian cells. However, many of the techniques and substances used for genetic engineering of animal cells and microorganisms are not directly applicable to genetic engineering involving plants.

As used herein, the term "plant" refers to

a multicellular differentiated organism that is
capable of photosynthesis, such as angiosperms and
multicellular algae. This does not include
microorganisms, such as bacteria, yeast, and



fungi. The term "plant cell" includes any cell derived from a plant; this includes undifferentiated tissue such as callus or crown gall tumor, as well as plant seeds, propagules, pollen, or plant embryos.

Ti and Ri Plasmids

The tumor-inducing (Ti) plasmid of 10 Agrobacterium tumefaciens has been proposed for use as a natural vector for introducing foreign genetic information into plant cells (Hernalsteen et al 1980; Rorsch and Schilpercort, 1978). Certain types of A. tumefaciens are capable of 15 infecting a wide variety of plant cells, causing crown gall disease. The process of infection is not fully understood. At least part of the Ti plasmid enters the plant cell. Various metabolic alterations occur, and part of the Ti plasmid is 20 inserted into the genome of the plant (presumably into the chromosomes). The part of the Ti plasmid that enters the plant genome is designated as "transferred DNA" (T-DNA). T-DNA is stably maintained in the plant DNA (Chilton et al, 1977; 25 Yadev et al, 1980; Willmitzer et al, 1980; Otten et al, 1981).

Research by several laboratories has led to the characterization of several structural (i.e., protein coding) genes located in T-DNA (Garfinkel et al 1981; Leemans et al 1982), as well as other DNA sequences which appear to serve various other functions. For example, two sequences referred to



as the "left border" and the "right border" appear to delineate T-DNA and may be involved in the process whereby T-DNA is transferred into plant chromosomes (Zambryski et al 1982).

5

10

25

A different species of Agrobacterium, A. rhizogenes, carries a "root-inducing" (Ri) plasmid which is similar to the Ti plasmid. Infection of a plant cell by A. rhizogenes causes hairy root disease. Like the Ti plasmid, a segment of DNA called "T-DNA" (also referred to by some researchers as "R-DNA") is transferred into the plant genome of an infected cell.

Various other bacteria are also reported to be capable of causing genetic transformation of plant cells, including A. rubi and certain bacteria of the genus Rhizobia which have been treated with a mutagenic agent. Hooykaas et al, at page 156 of Setlow and Holaender, 1979.

As used herein, the term "Ti plasmid" includes any plasmid (1) which is contained in a microorganism, other than a virus, which is capable of causing genetic transformation of one or more types of plants or plant cells, and (2) which contains a segment of DNA which is inserted into a plant genome. This includes Ri plasmids.

As used herein, the term "T-DNA" refers to a segment of DNA in or from a Ti plasmid (1) which has been inserted into the genome of one or more types of plant cells, or (2) which is contained in

a segment of DNA that is located between two



sequences of bases which are capable of serving as T-DNA borders. As used herein, the terms "T-DNA border" and "border" are determined and applied empirically; these terms shall refer to a sequence of bases which appears at or near the end of a segment of DNA which is transferred from a Ti plasmid into a plant genome.

Despite the existing knowledge of T-DNA and
Ti plasmids, no one prior to this invention has
been able to utilize these vectors for the
introduction of foreign genes which are expressed
in genetically modified plants. A variety of
obstacles to such use have been encountered in
genetic engineering efforts. Such obstacles
include:

- l) the large size (approximately 200,000 base pairs) and resulting complexity of Ti
 20 plasmids preclude the use of standard recombinant DNA techniques to genetically modify and/or insert foreign genes into specific sites in the T-DNA. For example, there are no known unique restriction endonuclease cleavage sites in a Ti plasmid (Leemans et al. 1982).
- 2) the T-DNA, which is inserted into and expressed in plant cells, contains genes which are involved in the production of high levels of phytohormones in the transformed plant cells (Leemans et al 1982). The high levels of phytohormones interfere with the normal metabolic and regenerative process of the cells, and prevent the formation of phenotypically normal plants from



the cells (Braun and Wood, 1976; Yang et al, 1980). Exceptions to this are rare cases where the T-DNA has undergone extensive spontaneous deletions in planta to eliminate those genes involved in phytohormone production. Under these conditions, normal plants are reported to be obtainable at low frequency (Otten et al, 1981). However, the T-DNA genes involved in phytohormone production could not be deleted prior to this invention, since they were very important in the identification and/or selection of transformed plant cells (Marton et al, 1979).

As described above, simple recombinant DNA 15 techniques for introducing foreign genes into plasmids are not applicable to the large Ti plasmid. As a result, several indirect methods have been developed and are discussed below. first reported use of the Ti plasmid as a vector 20 was in model experiments in which bacterial transposons were inserted into T-DNA and subsequently introduced into plant cells. bacterial transposons were reported to be stably maintained in the plant genome (Hernalsteens et al, 1980; Garfinkel et al 1981). However, in 25 these cases the transformed tumor tissues were found to be incapable of regeneration into normal plants, and there was no reported evidence for the expression of bacterial genes in the plant cells. In addition, because the insertion of bacterial 30 transposons is believed to be essentially random, a great deal of effort was required to identify and localize the position of the inserted DNA in these examples. Therefore, this approach is not



likely to be useful to introduce desired genes in a predictable manner into plants.

Other researchers have reported the use of intermediate vectors which replicate in both 5 E.coli and A. tumefaciens (Matzke and Chilton, 1981; Leemans et al 1981; Garfinkel et al, 1981). The intermediate vectors contain relatively small subfragments of the Ti plasmid which can be manipulated using standard recombinant DNA 10 techniques. The subfragments can be modified by the deletion of specific sequences or by the insertion of foreign genes at specific sites. intermediate vectors containing the modified T DNA subfragment are then introduced into A. 15 tumefaciens by transformation or conjugation. Double recombination between the modified T-DNA fragment on the intermediate vector and its wild-type counterpart on the Ti plasmid results in 20 the replacement of the wild-type copy with the modified fragment. Cells which contain the recombined Ti plasmids can be selected using appropriate antibiotics.

Various foreign DNA's have been inserted at specific sites in the T-DNA by this method and they have been reported to be stably transferred into plant cells (Matzke and Chilton, 1981, Leemans et al 1981, 1982). However, such foreign genes have not been reported to be capable of expression in plant cells, and the transformed plant cells remain incapable of regeneration into normal plants. Furthermore, in the procedure described above, it is preferred for a double



crossover event to occur, in order to substitute the modified DNA fragment for the wild-type copy. A single crossover results in the formation of a co-integrate plasmid which contains two copies of the T-DNA subfragments. This duplication is undesirable in these methods since homologous recombination, which can occur in A. tumefaciens cells or in plant cells, can result in the loss of the inserted foreign gene(s).

10

5

A major disadvantage of the above methods is that the frequency of double recombination is quite low, about 10⁻⁴ to 10⁻⁹ (Leemans et al, 1981) and it requires extensive effort to identify and isolate the rare double-crossover recombinants. As a result, the number and types of experiments which can be performed using existing methods for genetically engineering the Ti plasmid is severely limited.

20

15

Other Means for Inserting DNA into Plant Cells

reported for inserting DNA into plant cells. One such method involves the use of lipid vesicles, also called liposomes, to encapsulate one or more DNA molecules. The liposomes and their DNA contents may be taken up by plant cells; see, e.g., Lurquin, 1981. If the inserted DNA can be incorporated into the plant genome, replicated, and inherited, the plant cells will be transformed.



20

Other alternate techniques involve contacting plant cells with DNA which is complexed with either (a) polycationic substances, such as poly-L-ornithine (Davey et al, 1980), or (b) calcium phosphate (Krens et al, 1982). Using these techniques, all or part of a Ti plasmid has been reportedly inserted into plant cells, causing tumorigenic alteration of the plant cells.

Another method has been developed involving the fusion of bacteria, which contain desired plasmids, with plant cells. Such methods involve converting the bacteria into spheroplasts and converting the plant cells into protoplasts. Both of these methods remove the cell wall barrier from the bacterial and plant cells, using enzymic digestion. The two cell types can then be used together by exposure to chemical agents, such as polyethylene glycol. See Hasezawa et al, 1981.

However, all of the foregoing techniques suffer from one or more of the following problems:

- transformation efficiencies reported to
 date have been very low;
 - 2. only small DNA molecules can be inserted into plant cells;
- 3. only small-numbers of DNA molecules can be inserted into plant cells; and/or,
 - 4. a gene which is inserted into a plant cell will not be stably maintained by the plant



cell unless it is incorporated into the genome of the plant cell, i.e., unless the gene is inserted into a chromosome or plasmid that replicates in the plant cell.

5

10

15

30

For these and possibly other reasons, no one has yet reported expression of a gene inserted into a plant cell by any of the foregoing techniques, except for the tumorigenic transformations noted above.

Prior to this invention, no satisfactory method existed for the creation and identification of genetically transformed plant cells which could be routinely regenerated into morphologically normal plants.

SUMMARY OF THE INVENTION

This invention relates to a method for transforming plant cells, and to plant cells transformed by this method. This invention also relates to a method for regenerating differentiated plants from transformed plant cells, and to transformed plants.

This invention involves a first plasmid, such as pMON120, which has certain desired characteristics described below. A gene which is capable of being expressed in plant cells may be inserted into this plasmid to obtain a derivative plasmid, such as pMON128. For example, plasmid pMON128 contains a chimeric gene which expresses neomycin phosphotransferase II (NPT II), an enzyme



10

which inactivates certain antibiotics. The chimeric gene is capable of expression in plant cells.

The derivative plasmid is inserted into a suitable microorganism, such as Agrobacterium tumefaciens cells which contain Ti plasmids. In the A. tumefaciens cells, some of the inserted plasmids recombine with Ti plasmids to form a co-integrate plasmid; this is due to a region of homology between the two plasmids. Only a single crossover event is required to create the desired co-integrate plasmid.

Because of the characteristics of the
inserted plasmid of this invention, the resulting
co-integrate Ti plasmid contains the chimeric gene
and/or any other inserted gene within the T-DNA
region of the co-integrate plasmid. The inserted
gene(s) are surrounded by at least two T-DNA
borders, at least one of which was inserted into
the Ti plasmid by the crossover event. By means
of appropriate antibiotics, A. tumefaciens cells
which do not have co-integrate Ti plasmids with
inserted genes are killed.

25

30

A. tumefaciens cells with co-integrate plasmids are co-cultured with plant cells, such as protoplasts, protoplast-derived cells, plant cuttings, or intact plants, under conditions which allow the co-integrate Ti plasmids, or portions thereof, to enter the plant cells. Once inside the plant cells, a portion of the Ti plasmid which is surrounded by the two T-DNA borders is inserted



10

by natural processes into the plant genome. This segment of DNA contains the chimeric gene and/or any other desired gene(s). Preferably, the segment of vector DNA which is inserted into the plant genome does not contain any genes which would render the plant cell incapable of being regenerated into a differentiated, morphologically-normal plant. The transformed plant cell(s) may be regenerated into a morphologically-normal plant which will pass the inserted gene to its descendants.

A variety of uses exist for plants transformed by the method of this invention. For example, a gene which codes for an enzyme which inactivates a herbicide may be inserted into a plant. This would make the plant and its descendants resistant to the herbicide.

Alternately, a gene which codes for a desired mammalian polypeptide such as growth hormone, insulin, interferon, or somatostatin may be inserted into plants. The plants may be grown and harvested, and the polypeptide could be extracted from the plant tissue.

25

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a flow chart indicating the steps of this invention.

 $\underline{\text{FIG. 2}}$ represents the creation of pMON41, a plasmid used to construct pMON120.



35

- FIG. 3 represents the creation of M-4, an M13-derived DNA used to construct pMON109.
- FIG. 4 represents the creation of pMON54, a plasmid used to construct pMON109.
 - FIG. 5 represents the creation of pMON109, a plasmid used to construct pMON120.
- 10 <u>FIG. 6</u> represents the creation of pMON113, a plasmid used to construct pMON120.
- FIG. 7 represents the creation of plasmid pMON120, an intermediate vector with three restriction endonuclease cleavage sites which are suitable for the insertion of a desired gene.
- FIG. 8 represents the creation of pMON128, an intermediate vector which was obtained by

 inserting a chimeric NOS-NPT II kanamycin-resistance gene into pMON120.
- FIG. 9 represents the cointegration of pMON128 with a wild-type Ti plasmid by means of a single crossover event, thereby creating a co-integrate plasmid with multiple borders.
- FIG. 10 indicates the co-integration of pMON128 with a disarmed Ti-plasmid, thereby creating a non-tumorigenic cointegrate plasmid.
 - FIG. 11 is a graph comparing growth of transformed cells and non-transformed cells on kanamycin-containing medium.



DETAILED DESCRIPTION OF THE INVENTION

In one preferred embodiment of this invention, a variety of chimeric genes were inserted into plant cells using the steps that are summarized on the flow chart of Figure 1. As shown on Figure 1, three preliminary plasmids were prepared. Those plasmids were designated as:

10

15

- 1. pMON41, which contained a right border from a nopaline-type Ti plasmid, and the 5' portion of a nopaline synthase (NOS) gene. The construction of plasmid pMON41 is described below and shown in Figure 2.
- pMON109, which contained the 3' portion of a NOS gene, and a selectable marker gene (spc/str) which allowed for the selection of A.
 tumefaciens cells having co-integrate Ti plasmids with chimeric genes. The construction of plasmid pMON109 is described below and shown in Figures 3, 4, and 5.
- 3. pMON113, which contained a region of DNA
 with a sequence that is identical to the sequence
 within the T-DNA portion of an octopine-type Ti
 plasmid. This region was designated as the "left
 inside homology" (LIH) region. The construction
 of pMON113 is described below and shown in Figure
 30 6.

After these plasmids were assembled, each plasmid was digested by appropriate endonucleases



to obtain a desired fragment. Three fragments (one from each of the three plasmids) were assembled in a triple ligation to obtain the intermediate vector, plasmid pMON120, as shown in Figure 7.

Plasmid pMON120 plays a key role in the embodiment of this invention that is described in detail below. This plasmid has the following characteristics:

10

5

1. pMON120 has at least three unique restriction endonuclease cleavage sites (EcoRI, ClaI, and HindIII) which allow for the convenient insertion of any desired gene.

15

20

- 2. pMON120 will replicate within normal E. coli cells. However, it will not replicate within normal Agrobacterium cells unless it co-integrates with another plasmid, such as a Ti plasmid, which will replicate in Agrobacterium cells.
- 3. pMON120 carries a marker gene which codes for an enzyme which confers resistance to

 25 two antibiotics, spectinomycin (spc) and streptomycin (str). This gene, referred to as the spc/str gene, is expressed in E.coli and in A.tumefaciens, but not in plant cells. pMON120 does not carry genes which code for resistance to ampicillin or tetracycline.



10

15

- 4. pMON120 carries a sequence which is homologous to a sequence within the T-DNA portion of an octopine-type Ti plasmid of A. tumefaciens. This sequence is referred to as the "left inside homology" (LIH) region. This region of homology promotes a crossover event whereby pMON120, or a derivative of pMON120 such as pMON128, forms a co-integrate with the Ti plasmid if the two plasmids exist inside the same A. tumefaciens cell. By definition, the "co-integrate" plasmid is formed by a single crossover event. It contains all DNA sequences that previously existed in either the Ti plasmid or the pMON120-derived plasmid.
- 5. pMON120 carries a nopaline-type T-DNA "right border," i.e., a sequence which is capable of acting as one end (designated by convention as the right border) of a T-DNA sequence which is transferred from a Ti plasmid and inserted into the chromosome of a plant cell during transformation of the cell by A. tumefaciens.
- promoter) which codes for the expression of an enzyme, nopaline synthase (NOS). Once introduced into a plant cell, the NOS enzyme catalyzes the production of nopaline, a type of opine. In most types of plants, opines are non-detrimental compounds which accumulate at low levels; the presence of nopaline can be readily detected in plant tissue (Otten and Schilperoort, 1978). Opine genes may serve as useful marker genes to confirm transformation, since opines do not



normally exist in untransformed plant cells. If desired, the NOS gene in pMON120 may be rendered non-functional by a variety of techniques known to those skilled in the art. For example, a BamHI cleavage site exists within the coding portion of the NOS gene; a stop codon or other appropriate oligonucleotide sequence could be inserted into this site to prevent the translation of NOS.

- The relative location of the various 7. 10 genes, cleavage sites, and other sequences in pMON120 is very important to the performance of this invention. The entire pMON120 plasmid, or its derivative plasmid such as pMON128, will be contained in the co-integrate Ti plasmid. 15 However, only part of the co-integrate Ti plasmid (the modified T-DNA region) will be inserted into the plant genome. Therefore, only a part of the pMON120-derived plasmid will be inserted into the plant genome. This portion begins at the T-DNA 20 border, and stretches in one direction only to the region of homology. In pMON120, the NOS scorable marker, the spc/str selectable marker, and the three insertion sites are within the portion of pMON120 that would be transferred into the plant 25 genome. However, the pBR322-derived region next to the LIH, and the PvuI cleavage site, probably would not be transferred into the plant genome. Importantly, this arrangement of pMON120 and its 30 derivatives prevents the transfer of more than one region of homology into the plant genome, as discussed below.
- 8. pMON120 is about 8 kilobases long. This is sufficiently small to allow it to accomplish



all of the objectives of this invention. However, if desired, it may be made somewhat smaller by the deletion of one or more nucleotide sequences which are not essential, using methods which are known to those skilled in the art. Such a reduction in size might improve the efficiency or other characteristics of the plasmid when used for this invention or for other purposes, as may be determined by those skilled in the art.

10

15

20

25

30

It is recognized that a wide variety of intermediate vectors which differ from pMON120 in one or more respects may be prepared and utilized by those skilled in the art. For example, the NOS marker used for scoring transformed plant cells might be deleted, or replaced or supplemented by a different scorable or selectable marker. One such marker gene might comprise an antibioticresistance gene such as the NOS-NPT II-NOS chimeric gene described below. As another example, the spc/str marker gene used for selecting A. tumefaciens cells with co-integrate plasmids might be deleted, or replaced or supplemented by a different scorable or selectable marker that is expressed in Agrobacteria. another example, a variety of T-DNA borders (such as a nopaline-type "left" border, or an octopinetype left or right border) might be utilized. Similarly, more than one border (such as two or more nopaline right borders, or one nopaline right border and one octopine right border) might be inserted into the intermediate vector, in the desired orientation; this may increase the frequency of insertion of the T-DNA into the plant



genome, as may be determined by those skilled in the art. It is also possible to insert both left and right borders (of any type) into an intermediate vector. It is also possible to increase the length of the region of homology; this is likely to increase the frequency of the desired single crossover event (Leemans et al, 1981). It is also possible to select an appropriate region of homology from any type of desired plasmid, such as a nopaline or agropine Ti plasmid or an Ri plasmid; such regions will allow the intermediate vector to form a co-integrate with any desired plasmid.

15

20

10

5

Method of Creating pMON120

plasmid pMON120 was constructed from fragments derived from 3 other plasmids. These three plasmids were designated as pMON41, pMON109, and pMON113. The construction of each of these three plasmids is summarized below; additional information is provided in the examples.

25 <u>Plasmid pMON41</u> contributed a nopaline-type T-DNA right border and the 5' portion of a nopaline synthase (NOS) gene to pMON120. It was created by the following method.

A nopaline-type Ti plasmid, designated as the pTiT37 plasmid, may be digested with the HindIII endonuclease to produce a variety of fragments, including a 3.4 kb fragment which is designated as the HindIII-23 fragment. This



10

15

20

fragment contains the entire NOS gene and the T-DNA right border. The Applicants inserted a HindIII-23 fragment into a plasmid, pBR327 (Soberon et al, 1980), which had been digested with HindIII. The resulting plasmid, designated as pMON38, was digested with both HindIII and BamHI. This produced a 2.3 kb fragment which contains the nopaline-type right border and the 5' portion of a NOS gene (including the promoter region, the 5' non-translated region, and part of the structural sequence). This 2.3 kb fragment was inserted into a pBR327 plasmid which had been digested with HindIII and BamHI. The resulting plasmid was designated as pMON41, as shown in Figure 2.

A variety of strains of <u>A. tumefaciens</u> are publicly available from the American Type Culture Collection (Rockville, MD); accession numbers are listed in any ATCC catalog. Each strain contains a Ti plasmid which is likely to be suitable for use in this invention, as may be determined through routine experimentation by those skilled in the art.

25

Plasmid pMON109 contributed a spc/str selectable marker gene and the 3' portion of a NOS gene to pMON120. It was created by the following method.

30

Plasmid pMON38 (described above and shown on Figure 2) was digested with RsaI, which creates blunt ends as shown: 5'-GTAC

CATG

35



A 1.1 kb fragment was isolated, and digested with BamHI to obtain fragments of 720 bp and 400 bp, each of which had one blunt Rsa end and a cohesive BamHI end. These fragments were added to double stranded DNA from a phage M13 mp8 (Messing and 5 Vieira, 1982) which had been digested with Smal (which creates blunt ends) and BamHI. The mixture was ligated, transformed into cells and plated for recombinant phage. Recombinant phage DNA's which contained the inserted 720 bp fragment were 10 identified by the size of the BamHI-SmaI insert. One of those phage DNA's was designated as M-4, as shown in Figure 3. The 720 bp insert contained the 3' non-translated region (including the 15 poly-adenylation signal indicated in the figures by a heavy dot) of the NOS gene, as well as the 3' portion of the structural sequence of the NOS gene. The 720 bp insert is surrounded in M-4 by EcoRI and PstI cleavage sites, which were present 20 in the M13 mp8 DNA.

A bacterial transposon, designated as Tn7, is known to contain the spc/str gene, mentioned previously. The Tn7 transposon also contains a gene which causes the host cell to be resistant to the antibiotic trimethoprim. The exact location and orientation of the spc/str gene and the trimethoprim-resistance gene in Tn7, are not known. The Tn7 transposon may be obtained from a variety of cell strains which are publicly available. A strain of A. tumefaciens was isolated in which the Tn7 transposon had been inserted into the Hind III-23 region of a pTiT37 plasmid. The modified pTiT37 plasmid was



25

30

designated as pGV3106 (Hernalsteens et al, 1980).

Plasmid pGV3106 was digested with HindIII, and the fragments were shotgun-cloned into pBR327 plasmids which had been digested with HindIII. 5 These plasmids were inserted into E. coli cells, and cells which were ampicillin-resistant (due to a pBR327 gene) and trimethoprim-resistant (due to a Tn7 gene) were selected. The plasmid obtained 10 from one colony was designated as pMON31. plasmid contained a 6kb HindIII insert. insert contained the spc/str-resistance gene and trimethoprim-resistance gene from Tn7, and the 3' portion of a NOS gene (which came from the pTiT37 15 plasmid).

Plasmid pMON31 was reduced in size twice. The first reduction was performed by digesting the plasmid with EcoRI, diluting the mixture to remove an 850 bp fragment, and religating the large fragment. The resulting plasmid, designated as pMON53, was obtained from transformed cells selected by their resistance to ampicillin and streptomycin. Resistance to trimethoprim was not determined.

Plasmid pMON53 was further reduced in size by digesting the plasmid with ClaI, diluting the mixture to remove a 2 kb fragment, and religating the large fragment. The resulting 5.2 kb plasmid was designated as pMON54, as shown in Figure 4. This plasmid contains the spc/str gene.

Plasmid pMON54 was digested with EcoRI and



25

30

PstI, and a 4.8 kb fragment containing the spc/str gene was isolated. M-4 DNA was digested with EcoRI and PstI, and a 740 bp fragment containing the NOS 3' non-translated region was isolated. 5 These fragments were ligated together to form pMON64. In order to be able to obtain the NOS 3' portion and the spc/str gene on a single ? . EcoRI-BamHI fragment, the orientation of the spc/str gene was reversed by digesting pMON64 with ClaI and religating the mixture. Plasmids having the desired orientation were identified by cleavage using EcoRI and BamHI. These plasmids were designated as pMON109, as shown in Figure 5.

15 Plasmid pMON113 contributed a region of homology to pMON120 which allows pMON120 to form a co-integrate plasmid when present in A. tumefaciens along with a Ti plasmid. region of homology was taken from an octopine-type 20 Ti plasmid. In the Ti plasmid, it is located near the left T-DNA border, within the T-DNA portion of the Ti plasmid. This region of homology is designated as the "left inside homology" (LIH) region.

A region of homology may be derived from any type of plasmid capable of transforming plant cells, such as any Ti plasmid or any Ri plasmid. An intermediate vector can be designed which can form a co-integrate plasmid with whatever type of

plasmid the region of homology was derived from.

In addition, it might not be necessary for the region of homology to be located within the



T-DNA. For example, it may be possible for a region of homology to be derived from a segment of a Ti plasmid which contains a T-DNA border and a sequences of bases outside of the T-DNA region. Indeed, if the intermediate vector contains two appropriate T-DNA borders, it might be possible for the region of homology to be located entirely outside of the T-DNA region.

The Applicants obtained an <u>E. coli</u> culture with a pBR-derived plasmid containing the Bam-8 fragment of an octopine-type Ti plasmid. The Bam-8 fragment, which is about 7.5 kb, contains the left border and the LIH region of the Ti plasmid (Willmitzer et al, 1982; DeGreve et al, 1981). The Bam-8 fragment was inserted into the plasmid pBR327, which had been digested with BamHI. The resulting plasmid was designated as pMON90, as shown in Figure 6.

20

25

30

5

Plasmid pMON90 was digested with BglII, and a 2.6 kb fragment which contains the LIH region but not the left border was purified. The 2.6 kb fragment was treated with Klenow polymerase to convert the cohesive ends into blunt ends, and the fragment was digested with HindIII to obtain a 1.6 kb fragment (the desired fragment) and a 1 kb fragment. Both fragments were mixed with a pBR322 plasmid which had been digested with PvuII and HindIII. The mixture was ligated, and inserted into E. coli cells. The cells were selected for ampicillin resistance, and scored for the presence of a SmaI site which exists on the 1.6 kb fragment but not the 1 kb fragment. A colony having the



desired plasmid was identified, and the plasmid from this colony was designated as pMON113, as indicated by Figure 6.

To assemble pMON120, three fragments had to be isolated. Plasmid pMON41 was digested with PvuI and BamI, and a 1.5 kb fragment containing a nopaline-type right border and the 5' portion of a NOS gene was isolated. Plasmid pMON109 was digested with BamHI and EcoRI, and a 3.4 kb fragment containing a spc/str gene and the 3' part of a NOS gene was isolated. Plasmid pMON113 was digested with PvuI and EcoRI, and a 3.1 kb fragment containing the LIH region was isolated.

15

20

25

The three fragments were mixed together and ligated to form pMON120, as shown on Figure 7. A culture of <u>E. coli</u> containing pMON120 has been deposited with the American Type Culture Collection. This culture has been assigned accession number 39263.

It is recognized that a variety of different methods could be used to create pMON120, or any similar intermediate vector. For example, instead of the triple ligation, it would have been possible to assemble two of the desired fragments in a plasmid, and insert the third fragment into the plasmid.

30

Method of Using pMON120

As mentioned previously, pMON120 has three



unique cleavage sites (EcoRI, ClaI, and HindIII) which are suitable for the insertion of any desired gene. These cleavage sites are located in the portion of pMONI20 that will be inserted into a plant genome, so the inserted gene also will be inserted into the plant genome.

A variety of chimeric genes which are capable of expressing bacterial and mammalian polypeptides in plant cells have been created by the Applicants. These chimeric genes are described in detail in a separate application entitled "Chimeric Genes Suitable for Expression in Plant Cells," copending U.S. application serial number 458,414, filed on January 17, 1983.

- Those chimeric genes are suitable for use in this invention. They may be inserted into pMON120 to create a derivative plasmid, which may be utilized as described below.
- In one preferred embodiment of this 20 invention, a chimeric gene was created which comprises the following DNA sequences:
- a promoter region and a 5'
 non-translated region derived from a nopaline
 synthase (NOS) gene;
 - 2. a structural sequence derived from a neomycin phosphotransferase II (NPT II) gene; and
- 3. a 3' non-translated region derived from a NOS gene.



This chimeric NOS-NPT II-NOS gene was isolated on a DNA fragment having EcoRI ends. This fragment was inserted into the EcoRI cleavage site of pMON120, and the resulting plasmids (having chimeric gene inserts with opposite orientations) were designated as pMON128 and pMON129, as shown in Figure 8. Plasmid pMON129 has two copies of the chimeric gene; this may be a useful feature in certain types of work. Either plasmid may be utilized to transform plant cells, in the following manner. A culture of E. colicontaining pMON128 has been deposited with the American Type Culture Collection. This culture has been assigned accession number 39264.

15

5

10

Plasmid pMON128 (or any other plasmid derived by inserting a desired gene into pMON120) is inserted into a microorganism which contains an 20 octopine-type Ti plasmid (or other suitable plasmid). Suitable microorganisms include A. tumefaciens and A. rhizogenes which carry Ti or Ri plasmids. Other microorganisms which might also be useful for use in this invention include 25 other species of Agrobacterium, as well as bacteria in the genus Rhizobia. The suitability of these cells, or of any other cells known at present or hereafter discovered or created, for use in this invention may be determined through 30 routine experimentation by those skilled in the art.

The plasmid may be inserted into the microorganism by any desired method, such as



transformation (i.e., contacting plasmids with cells that have been treated to increase their uptake of DNA) or conjugation with cells that contain the pMON128 or other plasmids.

5

10

The inserted plasmid (such as pMON128) has a region which is homologous to a sequence within the Ti plasmid. This "LIH" region of homology allows a single crossover event whereby pMON128 and an octopine-type Ti plasmid combine with each other to form a co-integrate plasmid. See, e.g., Stryer, supra, at p. 752-754. Normally, this will occur within the A. tumefaciens cell after pMON128 has been inserted into the cell. Alternately, the co-integrate plasmid may be created in a different type of cell or in vitro, and then inserted into an A. tumefaciens or other type of cell which can transfer the co-integrate plasmid into plant cells.

20

15

The inserted plasmid, such as pMON128, combines with the Ti plasmid in the manner represented by Figures 9 or 10, depending upon what type of Ti plasmid is involved.

25

30

In Figure 9, item 2 represents the T-DNA portion of an octopine-type Ti plasmid. Item 4 represents the inserted plasmid, such as pMON128. When these two plasmids co-exist in the same cell, a crossover event can occur which results in the creation of co-integrate plasmid 6.

Co-integrate plasmid 6 has one left border 8, and two right borders 10 and 12. The two right



borders are designated herein as the "proximal" right border 10 (the right border closest to left border 8), and the "distal" right border 12 (the right border that is more distant from left border 8. Proximate right border 10 was carried by plasmid 4; the distal right border was contained on Ti plasmid 2 before co-integration.

A culture of <u>A. tumefaciens</u> GV3111 containing a co-integrate plasmid formed by pMON128 and wild-type Ti plasmid pTiB653 has been deposited with the American Type Culture Collection. This culture has been assigned accession number 39266.

15

10

5

When co-integrate Ti plasmid 6, shown in Figure 9, is inserted into a plant cell, either of two regions of DNA may enter the plant genome, T-DNA region 14 or T-DNA region 16.

20

T-DNA region 14 is bounded by left border 8 and proximate right border 10. Region 14 contains the chimeric gene and any other genes contained in plasmid 4, such as the spc/str selectable marker and the NOS scorable marker. However, region 14 does not contain any of the T-DNA genes which would cause crown gall disease or otherwise disrupt the metabolism or regenerative capacity of the plant cell.

30

25

T-DNA region 16 contains left border 8 and both right borders 10 and 12. This segment of T-DNA contains the chimeric gene and any other genes contained in plasmid 4. However, T-DNA region 16



also contains the T-DNA genes which are believed to cause crown gall disease.

Either of the foregoing T-DNA segments,

Region 14 or Region 16, might be transferred to
the plant DNA. This is presumed to occur at a
50-50 probability for any given T-DNA transfer.
This is likely to lead to a mixture of transformed
cells, some of which are tumorous and some or
which are non-tumorous. It is possible to isolate
and cultivate non-tumorous cells from the mixture,
as described in the examples.

An alternate approach has also been
developed which avoids the need for isolating tumorous from non-tumorous cells. Several mutant strains of A.tumefaciens have been isolated which are incapable of causing crown gall disease. Such strains are usually referred to as "disarmed" Ti plasmids. A Ti or Ri plasmid may be disarmed by one or more of the following types of mutations:

- 1. Removal or inactivation of one of the border regions. One such disarmed octopine
 25 plasmid, which has a left border but not a right border, is designated as pAL4421; this plasmid is contained in A. tumefaciens strain LBA4421 (Ooms et al, 1982; Garfinkel et al, 1981).
- 2. Removal or inactivation of the one or more of the "tumor morphology" genes, designated as the tmr and tms genes. See, e.g., Leemans et al, 1982.



Various other types of disarmed Ti plasmids may be prepared using methods known to those skilled in the art. See Matzke and Chilton, 1981; Leemans et al, 1981; Koekman et al, 1979.

5

10

15

20

Figure 10 represents an octopine-type Ti plasmid with a T-DNA region 22 which undergoes mutation to delete the tms and tmr genes and the right border. This results in a disarmed Ti plasmid with partial T-DNA region 24. plasmid 26 (such as pMON128) is inserted into a cell that carries the disarmed Ti plasmid 24, a crossover event occurs which creates a co-integrate Ti plasmid with disarmed T-DNA region 28. The LIH region of homology is repeated in this Ti plasmid, but the disarmed Ti plasmid does not contain any oncogenic genes. Alternately, if only the right border had been deleted from T-DNA region 22, then the tms and tmr genes and the octopine synthase (OCS) gene would be contained in the co-integrate disarmed Ti plasmid; however, they would have been located outside of the T-DNA borders.

25

30

The disarmed co-integrate Ti plasmid is used to infect plant cells, and T-DNA region 28 enters the plant genome, as shown by transformed DNA 30. Plant cells transformed by disarmed T-DNA 28 have normal phytohormone metabolism, and normal capability to be regenerated into differentiated plants.

After pMON128 is inserted into <u>A.</u>

35 <u>tumefaciens</u> cells, the desired crossover event



will occur in a certain fraction of the cells. Cells which contain co-integrate plasmids (whether virulent or disarmed) may be easily selected from other cells in which the crossover did not occur, in the following manner. Plasmid pMON120 and its 5 derivatives contain a marker gene (spc/str), which is expressed in A. tumefaciens. However, these plasmids do not replicate in A. tumefaciens. Therefore, the spc/str marker gene will not be replicated or stably inherited by A. tumefaciens 10 unless the inserted plasmid combines with another plasmid that can replicate in A. tumefaciens. most probable such combination, due to the region of homology, is the co-integrate formed with the Ti plasmid. A. tumefaciens cells which contain 15 this co-integrate plasmid can readily be identified and selected by growth of the cells on medium containing either spc or str, or both.

20 The Ti plasmid 28, shown in Figure 10, contains two LIH regions. It is possible that co-integrate Ti plasmids will undergo a subsequent crossover event, wherein the two LIH regions will recombine. This event is undesirable, since it 25 can lead to a deletion of the DNA between the LIH regions, including the chimeric gene. this is not likely to lead to serious difficulties, for two reasons. First, this event is likely to occur at a relatively low probability, such as about 10⁻². Second, plasmid 30 pMON120 and its derivatives have been designed so that the selectable marker gene (spc/str) is located in the region of DNA that would be deleted by the crossover event. Therefore, the selective



30

conditions that are used to identify and culture

Agrobacteria cells containing co-integrate

plasmids will also serve to kill the descendants

of cells that undergo a subsequent crossover event

which eliminates the chimeric gene from the Ti

plasmid.

Only one of the LIH regions in the co-integrate Ti plasmid will be inserted into the plant genome, as shown in Figure 10. 10 important feature results from the design of pMON120, and it distinguishes this co-integrate plasmid from undesired co-integrate plasmids formed by the prior art. The LIH region which lies outside of the T-DNA borders will not be 15 inserted into the plant genome. This leads to at least two important advantages. First, the presence of two LIH regions inserted into the plant genome could result in crossover events which would lead to loss of the inserted genes in 20 the transformed plant cells and their progeny. Second, the presence of two regions of DNA homology can significantly complicate efforts to analyze the DNA inserted into the plant genome (Matzke and Chilton, 1981). 25

After A. tumefaciens cells which contain the co-integrate Ti plasmids with the chimeric genes have been identified and isolated, the co-integrate plasmids (or portions thereof) must be inserted into the plant cells. Eventually, methods may be developed to perform this step directly. In the meantime, a method has been developed which may be used conveniently and with



good results. This method is described in two separate copending U.S. patent applications, entitled "Transformation of Plant Cells by Extended Bacterial Co-Cultivation" serial number 458,413, and "Rapid Culture of Plant Protoplasts," serial number 458,412, both of which were filed on January 17, 1983. The method described in those applications may be briefly summarized as follows.

10

15

20

25

30

5

The plant cells to be transformed are contacted with enzymes which remove the cell walls. This converts the plant cells into protoplasts, which are viable cells surrounded by membranes. The enzymes are removed, and the protoplasts begin to regenerate cell wall material. At an appropriate time, the A. tumefaciens cells (which contain the co-integrate Ti plasmids with chimeric genes) are mixed with the plant protoplasts. The cells are co-cultivated for a period of time which allows the A. tumefaciens to infect the plant cells. After an appropriate co-cultivation period, the A. tumefaciens cells are killed, and the plant cells are propagated.

Plant cells which have been transformed (i.e., cells which have received DNA from the co-integrate Ti plasmids) and their descendants may be selected by a variety of methods, depending upon the type of gene(s) that were inserted into the plant genome. For example, certain genes may cause various antibiotics to be inactivated; such



20

25

genes include the chimeric NOS-NPT II-NOS gene carried by pMON128. Such genes may serve as selectable markers; a group of cells may be cultured on medium containing the antibiotic which is inactivated by the chimeric gene product, and only those cells containing the selectable marker gene will survive.

markers in plant cells. For example, pMON120 and its derivative plasmids, such as pMON128, carry a nopaline synthase (NOS) gene which is expressed in plant cells. This gene codes for an enzyme which catalyzes the formation of nopaline. Nopaline is a non-detrimental compound which usually is accumulated at low quantities in most types of plants; it can be easily detected by electrophoretic or chromatographic methods.

If a plant is transformed by a gene which creates a polypeptide that is difficult to detect, then the presence of a selectable marker gene (such as the NOS-NPT II-NOS chimeric gene) or a scorable marker gene (such as the NOS gene) in the transforming vector may assist in the identification and isolation of transformed cells.

If desired, appropriate incantations may be recited at any time during the performance of this invention. The effects of such incantations upon the methods, substances, or cells of this invention are not fully understood. However, such incantations are believed to perform an important role in enhancing the awareness and appreciation



of scientific and other personnel for the importance of this invention and the steps involved therein. A wide variety of incantations are known to those skilled in the art; the choice of incantation(s) for use with any particular method, compound, or type of cell may be determined by personal preference. Such incantations may, if desired, be supplemented or replaced by a variety of other communicative methods and devices.

Virtually any desired gene may be inserted into pMON120 or other plasmids which are designed to form co-integrates with Ti or similar plasmids. For example, the Applicants have created a variety of chimeric genes, which are discussed in the previously-cited application, "Chimeric Genes Suitable for Expression in Plant Cells."

20

25

15

5

10

The suitability of any gene for use in this invention may be determined through routine experimentation by those skilled in the art. Such usage is not limited to chimeric genes; for example, this invention may be used to insert multiple copies of a natural gene into plant cells.

This invention is suitable for use with a wide variety of plants, as may be determined through routine experimentation by those skilled in the art. For example, this invention is likely to be useful to transform cells from any type of



10

plant which can be infected by bacteria from the genus Agrobacterium. It is believed that virtually all dicotyledonous plants, and certain monocots, can be infected by one or more strains of Agrobacterium. In addition, microorganisms of the genus Rhizobia are likely to be useful for carrying co-integrate plasmids of this invention, as may be determined by those skilled in the art. Such bacteria might be preferred for certain types of transformations or plant types.

Certain types of plant cells can be cultured in vitro and regenerated into differentiated plants using techniques known to those skilled in the art. Such plant types 15 include potatoes, tomatoes, carrots, alfalfa and sunflowers. Research in in vitro plant culture techniques is progressing rapidly, and methods are likely to be developed to permit the regeneration 20 of a much wider range of plants from cells cultured in vitro. Cells from any such plant with regenerative capacity are likely to be transformable by the in vitro co-cultivation method discussed previously, as may be determined through routine experimentation by those skilled 25 in the art. Such transformed plant cells may be regenerated into differentiated plants using the procedures described in the examples.

30

The <u>in vitro</u> co-cultivation method offers certain advantages in the transformation of plants which are susceptible to <u>in vitro</u> culturing and regeneration. However, this invention is not



limited to in vitro cell culture methods. For example, a variety of plant shoots and cuttings (including soybeans, carrots, and sunflowers) have been transformed by contact with A. tumefaciens cells carrying the co-integrate plasmids of this invention. It is also possible to regenerate virtually any type of plant from a cutting or shoot. Therefore, it may be possible to develop methods of transforming shoots or cuttings using virulent or preferably disarmed co-integrate plasmids of this invention or mixtures thereof, and subsequently regenerating the transformed shoots or cuttings into differentiated plants which pass the inserted genes to their progeny.

15

20

25

30

10

5

As mentioned previously, it is not essential to this invention that co-cultivation be utilized to transfer the co-integrate plasmids of this invention into plant cells. A variety of other methods are being used to insert DNA into Such methods include encapsulation of DNA in liposomes, complexing the DNA with chemicals such as polycationic substances or calcium phosphate, fusion of bacterial spheroplasts with plant protoplasts, microinjection of DNA into a cell, and induction of DNA uptake by means of electric current. Although such methods have not been used to insert DNA into plant cells with satisfactory efficiency to date, they are being actively researched and they may be useful for inserting foreign genes into plant cells, using the intermediate vectors and co-integrate plasmids of this invention, or plasmids derived therefrom.



10

15

20

· 25

This invention may be useful for a wide variety of purposes. For example, certain bacterial enzymes, such as 5-enol pyruvyl shikimate-3-phosphoric acid synthase (EPSP synthase) are inactivated by certain herbicides; other enzymes, such as glutathione-S-transferase (GST), inactivate certain herbicides. It may be possible to insert chimeric genes into plants which will cause expression of such enzymes in the plants, thereby causing the plants to become resistant to one or more herbicides. This would allow for the herbicide, which would normally kill the untransformed plant, to be applied to a field of transformed plants. The herbicide would serve as a weed-killer, leaving the transformed plants undamaged.

Alternately, it may be possible to insert chimeric genes into plants which will cause the plants to create mammalian polypeptides, such as insulin, interferon, growth hormone, etc. At an appropriate time, the plants (or cultured plant tissue) would be harvested. Using a variety of processes which are known to those skilled in the art, the desired protein may be extracted from the harvested plant tissue.

An alternate use of this invention is to create plants with high content of desired

30 substances, such as storage proteins or other proteins. For example, a plant might contain one or more copies of a gene which codes for a desirable protein. Additional copies of this gene may be inserted into the plant by means of this



invention. Alternately, the structural sequence of the gene might be inserted into a chimeric gene under the control of a different promoter which causes prolific transcription of the structural sequence.

The methods of this invention may be used to identify, isolate, and study DNA sequences to determine whether they are capable of promoting or 10 otherwise regulating the expression of genes within plant cells. For example, the DNA from any type of cell can be fragmented, using partial endonuclease digestion or other methods. fragments can be inserted randomly into plasmids 15 similar to pMON128. These plasmids, instead of having a full chimeric gene such as NOS-NPT II-NOS, will have a partial chimeric gene, with a cleavage site for the insertion of DNA fragments, rather than a NOS promoter or other promoter. 20 plasmids with inserted DNA are then inserted into A. tumefaciens, where they can recombine with the Ti plasmids. Cells having co-integrate plasmids are selected by means of the spc/str or other marker gene. The co-integrate plasmids are then 25 inserted into the plant cells, by bacterial co-cultivation or other means. The plant cells will contain a selectable marker structural sequence such as the NPT II structural sequence, but this structural sequence will not be 30 transcribed unless the inserted DNA fragment serves as a promoter for the structural sequence. The plant cells may be selected by growing them on medium containing kanamycin or other appropriate antibiotics.



10

Using this method, it is possible to evaluate the promoter regions of bacteria, yeast, fungus, algae, other microorganisms, and animal cells to determine whether they function as gene promoters in various types of plant cells. It is also possible to evaluate promoters from one type of plant in other types of plant cells. By using similar methods and varying the cleavage site in the starting plasmid, it is possible to evaluate the performance of any DNA sequence as a 5' non-translated region, a 3' non-translated region, or any other type of regulatory sequence.

As used herein, "a piece of DNA" includes

15 plasmids, phages, DNA fragments, and
polynucleotides, whether natural or synthetic.

As used herein, a "chimeric piece of DNA" is limited to a piece of DNA which contains at 20 least two portions (i.e., two nucleotide sequences) that were derived from different and distinct pieces of DNA. For example, a chimeric piece of DNA cannot be created by merely deleting one or more portions of a naturally existing 25 plasmid. A chimeric piece of DNA may be produced by a variety of methods, such as ligating two fragments from different plasmids together, or by synthesizing a polynucleotide wherein the sequence of bases was determined by analysis of the base 30 sequences of two different plasmids.

As used herein, a chimeric piece of DNA is limited to DNA which has been assembled, synthesized, or otherwise produced as a result of



man-made efforts, and any piece of DNA which is replicated or otherwise derived therefrom.

"Man-made efforts" include enzymatic, cellular, and other biological processes, if such processes occur under conditions which are caused, enhanced, or controlled by human effort or intervention; this excluses plasmids, phages, and polynucleotides which are created solely by natural processes. As used herein, the term

"derived from" shall be construed broadly.

Whenever used in a claim, the term "chimeric" shall be a material limitation.

As used herein, "foreign" DNA includes any
DNA which is inserted into a pre-existing plant
cell. A "foreign gene" is a gene which is
inserted into a pre-existing plant cell.

As used herein, a "marker gene" is a gene
which confers a phenotypically identifiable trait
upon the host cell which allows transformed host
cells to be distinguished from non-transformed
cells. This includes screenable, scorable, and
selectable markers.

25

30

As used herein, a "region of homology" refers to a sequence of bases in one plasmid which has sufficient correlation with a sequence of bases in a different plasmid to cause recombination of the plasmid to occur at a statistically determinable frequency. Preferably, such recombination should occur at a frequency which allows for the convenient selection of cells having combined plasmids, e.g., greater than I per



10⁶ cells. This term is described more fully in a variety of publications, e.g., Leemans et al, 1981.

5 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific embodiments of the invention discussed herein. Such equivalents are within the scope of this invention.

EXAMPLES

Example 1: Creation of Plasmid pMON41

15

20

25

30

A culture of E. coli, carrying a pBR325 plasmid (Bolivar, 1978) with the HindIII-23 fragment of pTiT37 (Hernalsteens, et al, 1980) inserted at the HindIII site, was obtained from Drs. M. Bevan and M.D. Chilton, Washington University, St. Louis, MO. Ten micrograms (ug) of the plasmid from this clone was digested with 10 units of HindIII (unless noted, all restriction endonucleases used in these constructions were purchased from New England Biolabs, Beverly, MA and used with buffers according to the supplier's instructions) for 1 hour at 37°C. The 3.4 kb HindIII-23 fragment was purified by adsorption on glass beads (Vogelstein and Gillespie, 1979) after separation from the other HindIII fragments by electrophoresis on a 0.8% agarose gel. purified 3.4 kb HindIII fragment (1.0 ug) was mixed with 1.0 ug of plasmid pBR327 DNA (Soberon, et al, 1980) that had been digested with both



HindIII (2 units, 1 hour, 37°C and calf alkaline phosphatase (CAP; 0.2 units, 1 hour, 37°C de-proteinized with phenol, ethanol precipitated, and resuspended in 10 ul of TE (10 mM Tris HCl, pH8, 1 mM EDTA). One unit of T4 DNA ligase (prepared by the method of Murray et al, 1979) was added to the fragment mixture. One unit is defined as the concentration sufficient to obtain greater than 90% circularization of one microgram of HindIII linearized pBR327 plasmid in 5 minutes at 22°C. The mixed fragments were contained in a total volume of 15 ul of 25 mM Tris-HCl pH8, 10 mM MgCl₂, 1 mM dithiothreitol, 200 uM spermidine HCl and 0.75 mM ATP (ligase buffer).

15

10

The mixture was incubated at 22°C for 3 hours and then mixed with E. coli C600 recA56 cells that were prepared for transformation by treatment with CaCl2 (Maniatis et al, 1982). 20 Following a period for expression of the ampicillin resistance determinant carried by the pBR327 vector, cells were spread on LB solid medium plates (Miller, 1972) containing ampicillin at 200 ug/ml. After incubation at 37°C for 16 25 hours, several hundred clones were obtained. Plasmid mini-preps (Ish-Horowicz and Burke, 1981) were performed on 24 of these colonies and aliquots of the plasmid DNA's obtained (0.1 ug) were digested with HindIII to demonstrate the 30 presence of the 3.4 kb HindIII fragment. plasmid demonstrated the expected structure and was designated pMON38. pMON38 DNA were prepared by Triton X-100 lysis and CsCl gradient procedure (Davis et al, 1980).



Fifty ug of pMON38 DNA were digested with HindIII and BamHI (50 units each, 2 hours, 37°C and the 2.3 kb HindIII-BamHI fragment was purified 5 as described above. The purified fragment (1 ug) was mixed with 1 ug of the 2.9 kb HindIII-BamHI fragment of the pBR327 vector purified as described above. Following ligation (T4 DNA ligase, 2 units) and transformation of E. coli 10 cells as described above, fifty ampicillin-resistant colonies were obtained. DNAs from twelve plasmid mini-preps were digested with HindIII and BamHI to ascertain the presence of the 2.3 kb fragment. One plasmid of the 15 correct structure was chosen and designated pMON41, as shown in Figure 2. A quantity of this DNA was prepared as described above.

20 Example 2: Creation of M13 Clone M-4

Thirty ug of plasmid pMON38 (described in Example 1) were digested with RsaI (30 units, 2 hours, 37°C and the 1100 bp RsaI fragment was 25 purified after separation by agarose gel electrophoresis using the glass bead method described in the previous example. The purified 1100 bp RsaI-RsaI fragment (1 ug) was digested with 2 units of BamHI and the BamHI was 30 inactivated by heating. This DNA was mixed with 0.2 ug of phage Ml3mp8RF DNA which had been previously digested with SmaI and BamHI (2 units each, 1 hour, 37°C and 0.2 units of calf alkaline phosphotase (CAP). Following ligation with 100 35 units of T4 DNA ligase, transformation of E. coli



JM101 cells as described in the previous example, the transformed cells were mixed with soft agar and plated under conditions that allow the identification of recombinant phage (Messing and 5 Vieira, 1982). Twelve recombinant phage producing cells were picked and RF plasmid mini-preps were obtained as described in the previous example. The RF DNAs were digested with BamHI and Smal to prove the presence of the 720 bp RsaI-BamHI 10 fragment. One of the recombinant RF DNAs carrying the correct fragment was designated M13 mp8 M-4. This procedure is represented in Figure 3. DNA was prepared using the procedures of Ish-Horowicz and Burke, 1981 and Colman et al, 1978. 15

Example 3: Construction of pMON109

20 Twenty ug of plasmid pGV3106 (Hernalsteens et al 1980, prepared by the method of Currier and Nester 1976) was digested with HindIII (20 units, 2 hours, 37°C and mixed with 2 ug of HindIII-digested pBR327. Following ligation (T4 DNA ligase, 2 units) and transformation of E. coli cells as described above, one colony resistant to trimethoprim (100 ug/ml) and ampicillin was obtained. Digestion of plasmid DNA from this cell demonstrated the presence of a 6 kb HindIII fragment. This plasmid was designated pMON31.

Plasmid pMON31 from a mini-prep (0.5 ug) was digested with EcoRI (1 unit, 1 hour, 37°C) and the endonuclease was inactivated by heating (10°C).



10

min, 70°C). The 8.5 kb plasmid fragment was re-circularized in a ligation reaction of 100 ul (T4 DNA ligase, 1 unit) and used to transform E. coli cells with selection for ampicillin and streptomycin (25 ug/ml) resistant colonies. Plasmid mini-prep DNA's from six clones were digested with EcoRI to ascertain loss of the 850 bp fragment. One plasmid lacking the 850 bp EcoRI fragment was designated pMON53. This plasmid was introduced into E. coli GM42 dam- cells (Bale et al, 1979) by transformation as described.

Plasmid pMON53 (0.5 ug) from a mini-prep prepared from dam- cells was digested with ClaI, and recircularized in dilute solution as described above. Following transformation of E. coli GM42 cells and selection for ampicillin and spectinomycin (50 ug/ml) resistant clones, fifty colonies were obtained. Digestion of plasmid mini-prep DNA's from six colonies showed that all lacked the 2 kb ClaI fragment. One of these plasmids was designated pMON54, as represented in Figure 4. Plasmid DNA was prepared as described in Example 1.

25

30

Plasmid pMON54 DNA (20 ug) was digested with EcoRI and PstI (20 units of each, 2 hours, 37°C) and the 4.8 kb fragment was purified from agarose gels using NA-45 membrane (Schleicher and Schuell, Keene, N.H.).

The purified 4.8 kb fragment (0.5 ug) was mixed with 0.3 ug of a 740 bp EcoRI-PstI fragment obtained from Ml3mp8 M-4 RF DNA (described in



10

Example 2) which was purified using NA-45 membrane. Following ligation (T4 DNA ligase, 2 units), transformation of <u>E. coli</u> GM42 dam- cells, and selection for spectinomycin resistant cells, twenty colonies were obtained. Plasmid mini-prep DNA's prepared from twelve of these clones were digested with PstI and EcoRI to demonstrate the presence of the 740 bp fragment. One plasmid carrying this fragment was designated pMON64. A quantity of this plasmid DNA was prepared as described in Example 1.

DNA (0.5 ug) of pMON64 was digested with ClaI (1 unit, 1 hour, 37°C), the ClaI was heat inactivated, and the fragments rejoined with T4 15 DNA ligase (l unit). Following transformation and selection for spectinomycin resistant cells, plasmid mini-preps from twelve colonies were made. The DNA's were digested with BamHI and 20 EcoRI to determine the orientation of the 2 kb ClaI fragment. Half of the clones contained the ClaI fragment in the inverse orientation of that in pMON64. One of these plasmids was designated pMON109, as represented in Figure 5. 25 prepared as described in Example 1.

Example 4: Creation of plasmid pMON113

Plasmid pNW31C-8,29C (Thomashow et al, 1980) was obtained from Dr. S. Gelvin of Purdue University, West Lafayette, IN. This plasmid carries the pTiA6 7.5 kb Bam-8 fragment. The Bam-8 fragment was purified from 50 ug of



BamHI-digested pNW31C-8,29C using NA-45 membrane as described in previous examples. The purified 7.5 kb Bam-8 fragment (1.0 ug) was mixed with 0.5 ug of pBR327 vector DNA which had been previously 5 digested with both BamHI (2 units) and 0.2 units of calf alkaline phosphatase (CAP) for 1 hour at 37°C the mixture was deproteinized and resuspended as described in previous examples. The mixed fragments were treated with T4 ligase (2 units), used to transform E. coli C600 recA cells and 10 ampicillin-resistant colonies were selected as described previously. Mini-preps to obtain plasmid DNA were performed on twelve of these clones. The DNA was digested with BamHI to demonstrate the presence of the pBR327 vector and 15 7.5 kb Bam-8 fragments. One plasmid demonstrating both fragments was designated pMON90. DNA was prepared as described in Example 1.

Twenty-five ug of pMON90 DNA were digested 20 with BglII (25 units, 2 hours, 37°C and the 2.6 kb BglII fragment was purified using NA-45 membrane. To create blunt ends, the fragment (2 ug) was resuspended in 10 ul of 50 mM NaCl, 6.6 mM Tris-HCl pH8, 6.6 mM MgCl, and 0.5 mM 25 dithiothreitol (Klenow Buffer). The 4 deoxy-nucleoside triphosphates (dATP, dTTP, dCTP, and dGTP) were added to a final concentration of 1 mM and one unit of E. coli large Klenow fragment of DNA polymerase I (New England Biolabs, Beverly, 30 MA) was added. After incubation for 20 minutes at 22°C, the Klenow polymerase was heat inactivated and 10 units of HindIII was added. The HindIII digestion was carried out for 1 hour at 370C and



then the enzyme was heat inactivated. HindIII-BglII (blunt) fragments (1 ug) were added to 0.25 ug of the 2.2 kb HindIII-PvuII fragment of pBR322 (Bolivar, et al, 1977) which had been 5 generated by HindIII and PvuII digestion then treating with calf alkaline phosphatase as described in previous examples. After ligation using 100 units of T4 DNA ligase, transformation of E. coli LE392 cells and selection of ampicillin-resistant colonies as described in 10 previous examples, nineteen colonies were obtained. Plasmid mini-preps were prepared from twelve colonies and digested with HindIII to determine the size of the recombinant plasmid and with Smal to determine that the correct fragment 15 had been inserted. One plasmid with the correct structure was designated pMON113, as shown in Figure 6. Plasmid DNA was prepared as described in Example 1.

20

Example 5: Creation of Plasmid pMON120

Example 3) were digested with EcoRI and BamHI (20 units each, 2 hours, 37°C) and the 3.4 kb
BamHI-EcoRI fragment was purified using NA-45 membrane as described in previous examples.

Twenty ug of plasmid pMON4l (described in Example 1) were digested with BamHI and PvuI (20 units each, 2 hours, 37°C) and the 1.5 kb BamHI-PvuI fragment purified using NA-45 membrane as described in previous examples.



Twenty ug of pMON113 DNA (described in Example 4) were digested with PvuI and EcoRI (2 units each, 2 hr, 37°C) and the 3.1 kb PvuI-EcoRI fragment was purified using NA-45 membrane as above. To assemble plasmid pMON120, the 3.1 kb 5 EcoRI-PvuI pMON113 fragment (1.5 ug) was mixed with 1.5 ug of the 3.4 kb EcoRI-BamHI fragment from pMON109. After treatment with T4 ligase (3 units) for 16 hours at 10°C, the ligase was inactivated by heating (10 minutes, 70°C and 5 10 units of BamHI was added. Digestion continued for 30 minutes at 37°C at which time the BamHI endonuclease was inactivated by heating as above. Next, 0.75 ug of the 1.5 kb PvuI-BamHI fragment from pMON41 was added along with T4 DNA ligase (2 15 units) and fresh ATP to 0.75 mM final concentration. The final ligase reaction was carried out for 4 hours at 22°C at which time the mixture was used to transform E. coli LE 392 cells with subsequent selection for spectinomycin 20 resistant cells as described previously. Plasmid mini-preps from twelve out of several thousand colonies were screened for plasmids of approximately 8 kb in size containing single sites 25 for BamHI and EcoRI. One plasmid showing the correct structure was designated pMON120, which is shown in Figure 7 with an alternate method of construction. pMON120 DNA was prepared as described in Example 1.

30

A culture of <u>E. coli</u> containing pMON120 has been deposited with the American Type Culture Collection. This culture has been assigned accession number 39263.



Example 6: Creation of Plasmids pMON128 and pMON129

Plasmid pMON75 (described in detail in a separate application entitled "Chimeric Genes Suitable for Expression in Plant Cells," previously cited) contains a chimeric NOS-NPT II-NOS gene. This plasmid (and pMON128, described below) may be digested by EcoRI and a 1.5 kb fragment may be purified which contains the NOS-NPT II-NOS gene.

Plasmid pMON120 was digested with EcoRI and treated with calf alkaline phosphatase. After phenol deproteinization and ethanol precipitation, 15 the EcoRI-cleaved pMONI20 linear DNA was mixed with 0.5 ug of the 1.5 kb EcoRI chimeric gene fragment from pMON75 or 76. The mixture was treated with 2 units of T4 DNA ligase for 1 hour at 22°C. After transformation of E. coli cells and 20 selection of colonies resistant to spectinomycin (50 ug/ml), several thousand colonies appeared. Six of these were picked, grown, and plasmid mini-preps made. The plasmid DNA's were digested 25 with EcoRI to check for the 1.5 kb chimeric gene insert and with BamHI to determine the orientation of the insert. BamHI digestion showned that in pMON128 the chimeric gene was transcribed in the same direction as the intact nopaline synthase 30 gene of pMON120. A culture of E. coli containing pMON128 has been deposited with the American Type Culture Collection. This culture has been assigned accession number 39264. The orientation of the insert in pMON129 was opposite that in



pMON128; the appearance of an additional 1.5 kb BamHI fragment in digests of pMON129 showed that plasmid pMON129 carried a tandem duplication of the chimeric NOS-NFT II-NOS gene, as shown in Figure 8.

Example 7: Creation of Co-integrate Plasmid pMON128::pTiB6S3TraC

10

5

Plasmid pMON128 (described in Example 6) was transferred to a chloramphenical resistant Agrobacterium tumefaciens strain GV3111=C58Cl carrying Ti plasmid pTiB6S3tra (Leemans, et al, 1982) using a tri-parental plate mating procedure, 15 as follows. 0.2 ml of a culture of E. coli carrying pMON128 was mixed with 0.2 ml of a culture of E. coli strain HBl01 carrying a pRK2013 plasmid (Ditta, et al, 1980) and 0.2 ml of GV3111 cells. The mixture of cells was cultured in Luria 20 Broth (LB), spread on an LB plate, and incubated for 16 to 24 hours at 30°C to allow plasmid transfer and generation of co-integrate plasmids. The cells were resuspended in 3 ml of 10 mM MgSO, 25 and 0.2 ml aliquot was then spread on an LB plate containing 25 ug/ml chloramphenicol and 100 ug/ml each of spectinomycin and streptomycin. incubation for 48 hr at 30°C approximately 10 colonies were obtained. One colony was chosen and grown at 30°C in LB medium containing 30 chloramphenicol, spectinomycin, and streptomycin at the concentrations given above.

A separate type of co-integrate plasmid



for use in control experiments was prepared by inserting pMONI20 into A. tumefaciens cells, and selecting for cells with co-integrate plasmids using spectinomycin and streptomycin, as described above. Like pMONI20, these plasmids do not contain the chimeric NOS-NPT II-NOS gene.

Example 8: Solutions Used in Plant Cell Cultures

10

5

The following solutions were used by the Applicants:

15		g	er liter
13	Enzyme mix:	Cellulysin Macerozyme	5 g 0.7 g
20		Ampicillin KH ₂ PO ₄ KNO ₃ CaCl ₂ MgSO ₄ .7H ₂ O KI	0.4 g 27.2 mg 101 mg 1.48 g 246 mg 0.16 mg
25		Cuso ₄ .5H ₂ O Mannitol ²	0.025 mg 110 g
	MS9:	MS salts(see below) Sucrose B5 vitamins (see below) Mannitol	4.3 g 30.0 g 1 ml 90.0 g
30	•	Phytohormones: Benzyladenine (BA) 2,4-D	0.5 mg 1 mg
35	MS-ES	MS salts Sucrose B5 Vitamins Mannitol Carbenicillin	4.3 g 30 g 1 ml 30 g 10 mg
40	•	Phytohormones: Indole acetic acid	0.1 mg



	MSO:	MS salts Sucrose B5 vitamins	4.3 g 30.0 g 1 ml
5	Feeder plate medium:	MS salts Sucrose B5 vitamins Mannitol Phytohormones:	4.3 g 30.0 g 1 ml 30.0 g
10		BA	0.5 mg
15	Ms2C	MS salts Sucrose B5 vitamins Phytohormones:	4.3 g 30 g 1 ml
13		chlorophenoxyacetic acid	2 mg
20	MS104:	MS salts Sucrose BS vitamins Phytohormones:	4.3 g 30.0 g 1 ml
25		BA NAA	0.1 mg 1 mg
23	MS11:	MS salts Sucrose B5 vitamins Phytohormones:	4.3 g 30.0 g 1 ml
30		Zeatin	1 mg
35	B5 Vitamin stock:	myo-inositol thiamine HCl nicotinic acid	100 g 10 g 1 g
33	Float rinse:	pyrodoxine HCl MS salts	l g
	riodt finse:	Sucrose PVP-40	0.43 g 171.2 g 40.0 g
40			±0.0 9

MS salts are purchased pre-mixed as a dry powder from Gibco Laboratories, Grand Island, N.Y.

45 Example 9: Preparation of Protoplasts

Mitchell petunia plants were grown in growth chambers with two or three banks of



fluorescent lamps and two banks of incandescent bulbs (about 5,000 lux). The temperature was maintained at a constant 21°C and the lights were on for 12 hours per day. Plants were grown in a 50/50 mix of Vermiculite and Pro-mix BX (Premier 5 Brands Inc., Canada). Plants were watered once a day with Hoagland's nutrient solution. Tissue was taken from dark green plants with compact, bushy growth. Leaves were sterilized in a solution of 10% commercial bleach and a small amount of 10 detergent or Tween 20 for 20 minutes with occasional agitation. Leaves were rinsed two or three times with sterile distilled water, Thin strips (about 1 mm) were cut from the leaves, 15 perpendicular to the main rib. The strips were placed in the enzyme mix at a ratio of about 1 g tissue to 10 ml enzymes. The dishes were sealed with parafilm, and incubated in the dark or under low, indirect light while gently agitating 20 continuously (e.g., 40 rpm on gyrotary shaker). Enzymic incubations generally were run overnight, about 16-20 hours.

The digestion mixture was sieved through a

68, 74, or 88 um screen to remove large debris and
leaf material. The filtrate was spun at 70-100 g
for five minutes to pellet the protoplasts. The
supernatant was decanted and the pellet was gently
resuspended in float rinse solution. This
suspension was poured into babcock bottles. The
bottles were filled to 2 or 3 cm above the base of
the neck. 1 ml of growth medium MS9 was carefully
layered on top of the float rinse.



The Babcock bottles were balanced and centrifuged at 500 to 1000 rpm for 10 to 20 minutes. The protoplasts formed a compact band in the neck at the interface. The band was removed with a pipette, taking care not to pick up any excess float rinse. The protoplasts were diluted into MS9. At this point, the protoplasts were washed with MS9 or diluted for plating without washing.

10

30

Protoplasts were suspended in MS9 medium at 5 x 10⁴ per ml, and plated into T-75 flasks, at 6 ml per flask. Flasks were incubated on a level surface with dim, indirect light or in the dark at 26-28°C. On the third day following the removal of the enzymes from the leaf tissue, MSO (medium which does not contain mannitol) was added to each flask, using an amount equal to one-half the original volume. The same amount of MSO is added again on day 4. This reduces the mannitol concentration to about 0.33 M after the first dilution, and about 0.25 M after the second dilution.

25 Example 10: Co-cultivation with Bacteria

On day 5 following protoplast isolation, five to seven day old tobacco suspension cultures (TXD cells) were diluted (if necessary) with MS2C medium to the point where 1 ml would spread easily over the surface of agar medium in a 100 x 15 mm petri plate .this is a 10 to 15% suspension (W/V).. The agar medium was obtained by mixing 0.8% agar with MS-ES medium, autoclaving the



30

mixture, and cooling the mixture until it solidifies in the plate. One ml of the TXD suspension was spread over 25 ml of feeder plate medium. An 8.5 cm disc of Whatman #1 filter paper was laid over the TXD feeder cells and smoothed out. A 7 cm disc of the same paper was placed in the center of the larger one.

Separately, aliquots of a culture of A.

tumefaciens cells (grown in yeast extract peptone medium) were added to the flasks which contained the plant cells. One set of aliquots contained cells with the pMON128::Ti co-integrate plasmids having chimeric NOS-NPT II-NOS genes. The other set of aliquots contained cells with the pMON120::Ti co-integrate plasmids, which do not have chimeric NOS-NPT II-NOS genes.

The bacteria were added to the flasks to a density of 10⁸ cells/ml. 0.5 ml of the cell mixture was spread in a thin layer on the surface of the 7 cm filter paper disc. The plates were wrapped in parafilm or plastic bags and incubated under direct fluorescent lighting, no more than five plates in a stack.

Within seven days, colonies were discernable. Within 14 days, the 7 cm discs, with colonies adhering to them, were transferred to new MSO agar medium (without feeder cells) containing 500 ug/ml carbenicillin, as well as 50 ug/ml of kanamycin sulfate (Sigma, St. Louis, MO). Within two weeks, vigorously growing green colonies could be observed on the plates which contained plant



tumefaciens strains containing the pMON128 co-integrate NOS-NPT II plasmid. No transformed colonies were detected on plates which contained plant cells that had been co-cultured with A. tumefaciens strains containing the pMON120 co-integrate plasmid. The kanamycin resistant transformants are capable of sustained growth in culture medium containing kanamycin. Southern blotting experiments (as described in E. Southern, J. Mol. Biol. 98: 503 (1975) confirmed that these cells contain the chimeric NOS-NPT II gene.

Both sets of transformed cells (and a third set of cells which had been transformed in the same manner by a chimeric gene coding for the enzyme NPT type I) were assayed for resistance to kanamycin. The results are indicated in Figure 11.

20

5

10

Example 11: Regeneration of Transformed Plants

The transformed kanamycin-resistant

colonies described in Example 10 contained both
tumorous and non-tumorous cells, as described in
Figure 9 and the related text. The following
procedure was used to isolate non-tumorous
transformed cells from tumorous transformed cells,
and to regenerate differentiated plant tissue from
the non-tumorous cells.

Colonies were grown on MS104 agar medium containing 30 ug/ml kanamycin sulfate and 500



ug/ml carbenicillin until they reached about 1 cm in diameter. Predominantly tumorous colonies appear a somewhat paler shade of green and are more loosely organized than predominantly non-tumorous colonies were removed from the MS104 medium by tweezers and placed upon MS11 medium containing 30 ug/ml kanamycin and 500 ug/ml carbenicillin. As the colonies continued to grow, colonies that appeared pale green and loosely organized were removed and discarded.

MS11 medium contains zeatin, a phytohormone which induces shooting formation in non-tumorous colonies. Several shoots were eventually observed 15 sprouting from kanamycin-resistant colonies. These shoots may be grown to a desired size, and cut off by a sharp blade, and inserted into agar medium without phytohormones, such as MSO, where it may generate roots. If desired, the medium may be supplemented by napthalene acetic acid to 20 induce rooting. The plants may be grown to a desired size in the agar medium, and then transferred into soil. If properly cultivated, such plants will grow to maturity and generate 25 seed. The acquired trait will be inherited by progeny according to classic Mendelian genetics.

References:

A. Bale et al, <u>Mut. Res. 59</u>: 157 (1979)
 F. Bolivar, <u>Gene 4</u>: 121 (1978)



- A. Braun and H. Wood, <u>Proc. Natl. Acad. Sci. USA 73</u>: 496 (1976)
- M. D. Chilton et al , Cell 11: 263 (1977)
- A. Colman et al, Eur. J. Biochem 91: 303-310
- 5 (1978)
 - T. Currier and E. Nester, <u>J. Bact. 126</u>: 157 (1976)
 - M. Davey et al, Plant Sci. Lett. 18: 307 (1980)
 - R. W. Davis et al, Advanced Bacterial Genetics
 - Cold Spring Harbor Laboratory, New York, (1980)
- 10 H. De Greve et al, Plasmid 6: 235 (1981)
 - G. Ditta et al, <u>Proc. Natl. Acad. Sci. USA 77</u>: 7347 (1980)
 - D. Garfinkel et al, Cell 27: 143 (1981)
 - S. Hasezawa et al, Mol. Gen. Genet. 182: 206
- 15 (1981)
 - J. Hernalsteens et al, Nature 287: 654 (1980)
 - D. Ish-Horowicz and J. F. Burke, <u>Nucleic Acids</u>
 Res. 9: 2989-2998 (1981)
 - B. Koekman et al, <u>J. Bacteriol</u>. 141: 129 (1979)
- 20 F. Krens et al, <u>Nature 296</u>: 72 (1982)



- J. Leemans et al, <u>J. Mol. Appl. Genet. 1</u>: 149 (1981)
- J. Leemans et al, The EMBO J. 1: 147 (1982)
- A. L. Lehninger, Biochemistry, 2nd ed. (Worth
- 5 Publ., 1975)
 - P. Lurquin, Nucleic Acids. Res. 6: 3773 (1979)
 - T. Maniatis et al, <u>Molecular Cloning</u>, A <u>Laboratory</u>
 <u>Manual</u> (Cold Spring Harbor Labs, 1982)
 - L. Marton et al, Nature 277: 129 (1979)
- 10 T. Matzke and M-D Chilton, <u>J. Mol. Appl. Genet. 1</u>: 39 (1981)
 - J. Messing et al, Nucleic Acids Res. 9: 309 (1981)
 - J. Messing and J. Vieira, Gene 19: 269-276 (1982)
 - J. Miller, Experiments in Molecular Genetics, Cold
- 15 Spring Harbor Laboratory, N.Y. (1972)
 - N. Murray et al, <u>J. Mol. Biol. 132</u>: 493 (1979)
 - G. Ooms et al, <u>Plasmid 7</u>: 15 (1982)
 - L. Otten and R. Schilperoort, <u>Biochim. Biophys</u>
 <u>Acta 527</u>: 497 (1978)
- 20 L. Otten, Mol. Gen. Genet. 183: 209 (1981)
 - R. Roberts, Nucleic Acids Res. 10: r117 (1982)
 - A. Rorsch and R. Schilperoort, <u>Genetic</u>
 <u>Engineering</u>, 189 Elsevier/North Holland, N.Y.
 (1978)
- J. K. Setlow and A. Hollaender, <u>Genetic</u>

 <u>Engineering</u>, <u>Principles</u> and <u>Methods</u> (Plenum Press 1979)
 - X. Soberon et al, <u>Gene-9</u>: 287 (1980)
 - L. Stryer, Biochemistry, 2nd. ed. (W. H. Freeman
- 30 and Co., 1981)
 - M. Thomashow et al, <u>Cell 19</u>: 729 (1980)
 - B. Vogelstein and D. Gillespie, <u>Proc. Natl. Acad.</u>
 <u>Sci.</u>: 615-619 (1979)



- L. Willmitzer et al, Nature 287: 359 (1980)
- L. Willmitzer et al, The EMBO J 1: 139 (1982)
- N. Yadev et al, <u>Nature 287</u>: 1 (1980)
- F. Yang et al, Mol. Gen. Genet. 177: 707 (1980)
- P. Zambryski et al, <u>J. Mol. Appl. Genet. 1</u>: 361 (1982)



CLAIMS

- 1. A method of creating transformed plant cells, comprising the following steps:
- a) culturing a microorganism containing
 (1) a first plasmid containing at least one first gene
 that is expressed in plant cells and at least one
 second gene which serves as a marker in a selected
 microorganism, and (2) a Ti second plasmid, under
 conditions which allow the first plasmid to recombine
 with the Ti second plasmid in the microorganism,
 thereby creating a third plasmid having at least one
 T-DNA border on each side of the first gene;
- b) selecting those microorganismscontaining the third plasmid;
 - c) inserting the third plasmid, or a portion therof, into plant cells; and
- d) culturing the plant cells under conditions which allow a segment of DNA from the
 20 third plasmid to be inserted into the genome of the plant cells.
 - 2. A method of Claim 1 wherein the third plasmid is a co-integrate plasmid formed by a single crossover event between the first and second plasmids.



20

25

- 3. A method of Claim 1 wherein the first gene comprises a promoter region derived from a gene which is expressed in a plant cell, coupled to a structural sequence which is heterologous with respect to the promoter region.
- 4. A method of Claim 1 wherein the first plasmid does not autonomously replicate in the selected microorganism.
- 5. A method of Claim 1 wherein the
 microorganism is selected from the group consisting of
 Agrobacterium tumefaciens, Agrobacterium rhizogenes,
 and Agrobacterium rubi.
- 6. A method of Claim 1 wherein the third plasmid, or a portion thereof, is inserted into the plant cells by co-cultivating the microorganism with the plant cells.
 - 7. A method of Claim 1 wherein the Ti second plasmid is a derivative of a tumor-inducing plasmid, from which one or more of the following nucleotide sequences have been deleted:
 - a) a sequence capable of acting as a T-DNA border sequence:
 - b) a "tumor-morphology-shooting" sequence;
 or
 - c) a "tumor-morphology-rooting" sequence.



- 8. A method of Claim 1 wherein the first gene is expressed in plant cells into polypeptides which catalyze the detoxification of one or more phytotoxic substances.
- 9. A method of Claim 1 wherein the transformed plant cells are capable of being regenerated into morphologically normal plants.
- 10. A method of Claim 1 wherein the transformed plant cells are phenotypically identical to untransformed plant cells with the exception of the ability to express one or more genes that were contained on the first plasmid.
 - 11. A method of Claim 1 wherein the transformed plant cells are not tumorous.
- 12. A method of Claim 1 wherein the transformed plant cells have non-tumorous phytohormone characteristics.
- 13. A method of transforming plant cells, comprising inserting into the plant cells a

 20 co-integrate plasmid, or a portion thereof, which was formed by a single crossover event between a first plasmid and a Ti second plasmid, wherein the co-integrate plasmid contains a region comprising:
 - a) a first T-DNA border;
- b) a gene which is expressed in plant cells; and
 - c) a second T-DNA border which is complementary to the first T-DNA border,



11

wherein the region does not contain any sequences which would render the plant cells incapable of being regenerated into morphologically normal plants.

- 14. A method of Claim 13, wherein the co-integrate plasmid contains a gene which is capable of serving as a marker gene in the plant cells.
 - 15. 'Plant cells transformed by the method of Claim 1 which contain a foreign gene which is expressed.
- 16. Plant cells transformed by the method of Claim 3 which contain a foreign gene which is expressed.
- 17. Plant cells transformed by the method of Claim 13 which contain a foreign gene which is expressed.
 - 18. Morphologically normal plants which express one or more foreign genes.
 - 19. Plants of Claim 18 wherein the foreign genes are chimeric genes.
- 20. Plant cells derived from plants of Claim 18.
 - 21. Plant cells derived from plants of Claim 19.
- 22. Plant cells of Claim 18 wherein the foreign genes are expressed to create polypeptides which catalyze the detoxification of one or more phytotoxic substances.



- 23. A method of regenerating differentiated plant tissue from a mixture of tumorous and non-tumorous cells, comprising the following steps:
- a) cultivating the mixture of cells in contact with one or more phytohormones which promote the growth of non-tumorous cells; and
- b) cultivating the mixture of cells in contact with one or more phytohormones which promote
 shoot or root growth from non-tumorous cells.
 - 24. A method of Claim 23 wherein the cells are capable of expressing a foreign gene which is not located on a wild-type Ti plasmid.
- 25. A differentiated plant regenerated by the method of Claim 24.
 - 26. Plant cells derived from plants of Claim 25.
 - 27. A method of creating polypeptides, comprising the following steps:
- a) creating transformed plant cells by the method of Claim 1;
 - b) regenerating the transformed plant cells to create transformed differentiated plants; and
- c) cultivating the transformed

 25 differentiated plants under conditions which cause
 plant cells to express the first gene.



10 -

- 28. A method of Claim 27 wherein the first gene comprises a chimeric gene with a structural sequence that is heterologous with respect to the promoter region.
- 29. A method of reducing the growth of undesired plants, comprising the following steps:
 - a) planting desired propagules that are derived from a differentiated, genetically transformed plant which expresses an inheritable foreign gene that causes the transformed plant to acquire the trait of resistance to one or more phytotoxic substances, in an area which contains undesired plants or plant propagules; and
- b) administering to the area a phytotoxic substance at a concentration which reduces the growth of the undesired plants while not substantially impeding the growth of plants which express the foreign gene from the desired propagales.
- 30. A method of Claim 29 wherein the
 20 foreign gene is expressed into a polypeptide that
 catalyzes the detoxification of the phytotoxic
 substance.
- 31. A method of Claim 29 wherein the foreign gene is expressed into a polypeptide that is deactivated by the phytotoxic substance.
 - 32. Plant seed derived from plant cells transformed by the method of Claim 1.



- 33. Plant seed derived from plant cells transformed by the method of Claim 13.
- 34. Plant seed derived from plants created by the method of Claim 23.









FIG. I.














OMPI WIPO WIPO WIPO




BUREAU OMPI WIPO WIPO NATIONA






BUREAU OMPI WIPO WIPO WIPO



BUREAU OMPI WIPO WIPO WIPO






FIG.9.






FIG.10.






FIG.II.



ACCORDING to JUNE 1990 A JUNE 1 STATE AND A JUNE 1990 A JUNE 1 STATE ACCORDING TO JUNE 1990 A JUNE 199	Minimum Occumentation Searched Classification System Classification Symbols 435/172,240,68 U.S. 47/1,58 Documentation Searched other than Minimum Occumentation to the Estent that such Documents are included in the Fields Searched to the Estent that such Documents are included in the Fields Searched to the Estent that such Documents are included in the Fields Searched to the Estent that such Documents are included in the Fields Searched to the Estent that such Documents are included in the Fields Searched to the Estent that such Document are included in the Fields Searched to the Estent that such Document are included in the Fields Searched to the Estent that such Document are included in the Fields Searched to the Estent that such Document are included in the Fields Searched to the Estent that such Document are included in the Fields Searched to Claim No. 1 X N, Schell et al, Genetic Engineering to Biotechnology		International Application No	/ʊs84/00050
II. DOCUMENTS CONSIDERED TO BE RELEVANT 14 III. DOCUMENTS CONSIDERED TO BE RELEVANT 14 ISOSOPY Citation of Document, 15 with Indication, where appropriate, of the relevant passages 17 IV. N. Schell et al., Genetic Engineering to Biotechnology - 1-34 The Critical Transition Edited by W.J. Whelam and Sandra Black Published by John Wiley and Sons Ltd. pages 41-52. IV. N. Otten et al., Mol. Gen. Genet. vol 183 pages 209-213 15-21,23-26, (4981) Y. N., Otten et al., Mol. Gen. Genet. vol 183 pages 209-213 22,29-31 (1981) Y. N., Matzke et al., J. of Mol. Appl. Genet. vol no. 1 pages 39-49 (1981) Y. N., Matzke et al., J. of Mol. Appl. Genet. vol no. 1 pages 39-49 (1981) Y. N., Leemans et al., J. of Mol. Appl. Genet. vol 1 no. 2 l-34 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 pages 149-164 (1981) **Social categories of cited cocuments: 19 p	III. DOCUMENTS CONSIDERED TO BE RELEVANT! III. DOCUMENTS CONSIDERED TO BE RELEVANT! Italegory Citation of Document, 14 with indication, where cognomate, of the Felerant assessages 1 X N, Schell et al, Genetic Engineering to Biotechnology - The Critical Transition Edited by W.J. Whelam and Sandra Black Published by John Wiley and Sons Ltd. pages 41-52. X N, Otten et al, Mol. Gen. Genet. vol 183 pages 209-213 15-21,23-26, (4981) Y N, Otten et al, Mol. Gen. Genet. vol 183 pages 209-213 22,29-31 (1981) Y N, Matzke et al, J. of Mol. Appl. Genet. vol no. 1 1-34 pages 39-49 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol no. 1 1-34 pages 39-49 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol 1 no. 2 1-34 pages 149-164 (1981) One comment affining the grantal state of the s			
Minimum Documentation Searched 435/172,240,68 U.S. 47/1,58 Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched Documents Considered to Be Relevant	U.S. 435/172,240,68 U.S. 47/1,58 Decumentation Searched other than Minimum Documentation to the Extent trial such Documents are included in the Pields Searched 1 Decuments to the Extent trial such Documents are included in the Pields Searched 1 Elegony Clisting of Document, 14 with indication, where soproniate, of the relevant passages 11 X. N. Schell et al, Genetic Engineering to Biotechnology — The Critical Transition Edited by W.J. Whelan and Sandra Black Published by John Wiley and Sons Ltd. pages 41–52. X. N. Otten.et al, Mol. Gen. Genet. vol 183 pages 209–213 15–21,23–26, (3981) Y. N. Otten et al, Mol. Gen. Genet. vol 183 pages 209–213 22,29–31 (1981) Y. N. Matzke et al, J. of Mol. Appl. Genet. vol 10. 1 1–34 pages 39–49 (1981) Y. N. Leemans et al, J. of Mol. Appl. Genet. vol 10. 2 1–34 Y. N. Leemans et al, J. of Mol. Appl. Genet. vol 1 no. 2 1–34 The Comment and have those decision or after the international filing sale with the comment of the same and the state of the same and the pages 149–164 (1981) **Saccial categories of cited documents: 13 **Comment and may those doubts on another claimfol or cited to consider and the pages 149–164 (1981) **Saccial categories of cited documents: 13 **Comment and may those doubts on another claimfol or cited to consider and the pages 149–164 (1981) **Comment referring to an oral disclaure, use, exhibition or of the comments to consider the consideration of the consideration and the pages 149–164 (1981) **Comment referring to an oral disclaure, use, exhibition or of the comments of the same sater family and comments are considered to consider the comment of the same sater family and comments are considered to consider the consideration and consider			
U.S. 435/172,240,68 435/172,240,68 Documentation Searched other than Minimum Documentation to the Estent that such Documents are included in the Fields Searched: Documents considered to BE RELEVANT!	U.S 435/172,240,68 435/172,240,68 Documentation Searched other than Minimum Documentation to the Estant that such Documents are included in the Fields Searched: Documents Considered To BE RELEVANT!* Iterative Considered To Be Relevant to Claim No.	II. FIELDS SEARCHED		
U.S 435/172,240,68 47/1,58 Documentation Searched other than Minimum Documentation to the Estent that such Documents are included in the Fields Searched 3 II. DOCUMENTS CONSIDERED TO BE RELEVANT 11 Imagent Citation of Document, 15 with Indication, where sopropriate, of the relevant passages 11 X N, Schell et al., Genetic Engineering to Biotechnology 1-34 —The Critical Transition Edited by WJ. Whelan and Sandra Black Published by John Wiley and Sons Ltd. pages 41-52. X N, Otten et al., Mol. Gen. Genet. vol 183 pages 209-213 15-21,23-26, (4981) Y N, Otten et al., Mol. Gen. Genet. vol 183 pages 209-213 22,29-31 (1981) Y N, Matzke et al., J. of Mol. Appl. Genet. vol no. 1 1-34 pages 39-49 (1981) Y N, Leemans et al., J. of Mol. Appl. Genet. vol 1 no. 2 1-34 Pages 149-164 (1981) **Saecial categories of cited documents: 12 **Comment which may in on counts on shorty claim(5) or categories and counts are considered and the consideration be defined and the consideration and counts an investment size of the counts and the consideration and counts and the consideration and counts an investment size of the counts and the consideration and counts and counts and the consideration and counts and counts and counts and the consideration and counts and count	U.S 435/172,240,68 47/1,58 Documentation Searched other than Minimum Documentation to the Extent triat such Documents are included in the Pields Searched 1 III. DOCUMENTS CONSIDERED TO BE RELEVANT 14 Legory Citation of Document, 15 with indication, where appropriate, of the relevant passages 11 Relevant to Claim No. 1 X N, Schell et al, Genetic Engineering to Biotechnology - The Critical Transition Edited by W.J. Whelan and Sandra Black Published by John Wiley and Sons Ltd. pages 41–52. X N, Otten et al, Mol. Gen. Genet. vol 183 pages 209–213 15–21,23–26, (3981) Y N, Otten et al, Mol. Gen. Genet. vol 183 pages 209–213 22,29–31 (1981) Y N, Matzke et al, J. of Mol. Appl. Genet. vol no. 1 1–34 pages 39–49 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol no. 1 1–34 pages 149–164 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol ino. 2 1–34 pages 149–164 (1981) **Total accument admining the general state of the art which is not considered to be of particular restance and considered to the page of considered to the page of consideration of confideration of consideration and confideration of con	Minimum Docum		
Documentation Searched other than Minimum Documentation to the Estent that such Documents are included in the Fields Searched 1 Documents Considered to Be Relevant 11 Legary Citation of Document, 15 with Indication, where appropriate, of the relevant passages 11 Relevant to Claim No. 14 N. Schell et al., Genetic Engineering to Biotechnology - 1-34 The Critical Translation Edited by W.J. Whelan and Sandra Black Published by John Wiley and Sons Ltd. pages 41-52. X. N. Otten.et al., Mol. Gen. Genet. vol 183 pages 209-213 15-21,23-26, (4981) Y. N. Otten.et al., Mol. Gen. Genet. vol 183 pages 209-213 22,29-31 (1981) Y. N. Matzke et al., J. of Mol. Appl. Genet. vol no. 1 1-34 pages 39-49 (1981) Y. N. Leemans et al., J. of Mol. Appl. Genet. vol 1 no. 2 1-34 Pages 149-164 (1981) Y. N. Leemans et al., J. of Mol. Appl. Genet. vol 1 no. 2 1-34 Pages 149-164 (1981) Y. N. Ceument exchange the specified of application by distinct the international filing cale of current specified in the property of the property of the control of the property of the control of the property of the control of the property of the control of the c	Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched 1 Documents Considered to BE RELEVANT 14	lassification System	Classification Symbols	
Special categories of cited documents: Special categories of cited documents are included in the Fields Searched	II. DOCUMENTS CONSIDERED TO BE RELEVANT!* Itegary Citation of Document, 14 with Indication, where experiently to Biotechnology - The Critical Transition Edited by W.J. Whelan and Sandra Black Published by John Wiley and Sons Ltd. pages 41-52. X			
Citation of Document, 16 with Indication, where appropriate, of the relevant passages 17 Relevant to Claim No. 18	Relevant to Claim No. Rele			•
Citation of Document, 16 with Indication, where appropriate, of the relevant passages 17 Relevant to Claim No. 18	Relevant to Claim No. Rele			
Citation of Document, 16 with Indication, where appropriate, of the relevant passages 17 Relevant to Claim No. 18	Citation of Document, is with indication, where appropriate, of the relevant passages if Relevant to Claim No.	II. DOCUMENTS CONSIDERED TO BE RELEVANT 14		· · · · · · · · · · · · · · · · · · ·
X N, Schell et al, Genetic Engineering to Biotechnology . 1-34 -The Critical Transition Edited by W.J. Whelan and Sandra Black Published by John Wiley and Sons Ltd. pages 41-52. X N, Otten.et al, Mol. Gen. Genet. vol 183 pages 209-213 15-21,23-26, (4981) 32-34 Y N, Otten et al, Mol. Gen. Genet. vol 183 pages 209-213 22,29-31 (1981) Y N, Matzke et al, J. of Mol. Appl. Genet. vol no. 1 1-34 pages 39-49 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol 1 no. 2 1-34 pages 149-164 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol 1 no. 2 1-34 pages 149-164 (1981) """ "Secument affining the general state of the art which is not considered to be of particular researce." """ "decument which may those good not after the international fining cate." """ "decument which may those good not after the international fining cate of the state of the	**Special categories of cited documents: 19 **Special categories of cited documents: 19 **Special categories of cited documents: 19 **No, Otten et al., Mol. Gen. Genet. vol 183 pages 209-213 15-21,23-26, (4981) **Y No, Otten et al., Mol. Gen. Genet. vol 183 pages 209-213 22,29-31 (1981) **Y No, Matzke et al., J. of Mol. Appl. Genet. vol no. 1 1-34 pages 39-49 (1981) **Y No, Leemans et al., J. of Mol. Appl. Genet. vol no. 1 1-34 pages 39-49 (1981) **Y No, Leemans et al., J. of Mol. Appl. Genet. vol 1 no. 2 1-34 pages 149-164 (1981) **This is accument but bulbished on or after the international filing cate accument which may it how counts on around claims(s) or accument which may it how counts can around categories and counter international filing cate accument reterring to an oral discious of counter internation and oral categories are special categories and categories an		opropriate, of the relevant passages 1:	Relevant to Claim No. 15
Ltd. pages 41–52. X N, Otten et al, Mol. Gen. Genet. vol 183 pages 209–213 15–21,23–26, (4981) Y N, Otten et al, Mol. Gen. Genet. vol 183 pages 209–213 22,29–31 (1981) Y N, Matzke et al, J. of Mol. Appl. Genet. vol no. 1 1–34 pages 39–49 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol 1 no. 2 1–34 pages 149–164 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol 1 no. 2 1–34 pages 149–164 (1981) **The later document subsisted an article of the art which is not remained an includer researce in the observation of the article o	Ltd. pages 41-52. X N, Otten.et al, Mol. Gen. Genet. vol 183 pages 209-213 15-21,23-26, (4981) Y N, Otten et al, Mol. Gen. Genet. vol 183 pages 209-213 22,29-31 (1981) Y N, Matzke et al, J. of Mol. Appl. Genet. vol no. 1 1-34 pages 39-49 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol 1 no. 2 1-34 pages 149-164 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol 1 no. 2 1-34 pages 149-164 (1981) **Total additional consistence to be of particular relevance to be of particular relevance to be of particular relevance. The deciment but published on or after the international fifting date and critical relevance to be of particular relevance to be consistence to be of particular relevance to be consistent or state that the priority case claimed control or other special reason to specified in the priority case claimed. The pages of the pages	-The Critical Transition Edi	ited by W.J. Whelan	1-34
Y N, Matzke et al, J. of Mol. Appl. Genet. vol no. 1 1-34 pages 39-49 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol no. 1 1-34 pages 149-164 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol 1 no. 2 1-34 pages 149-164 (1981) *Touristic class of cited documents: 15	Y N, Otten et al, Mol. Gen. Genet. vol 183 pages 209-213 22,29-31 (1981) Y N, Matzke et al, J. of Mol. Appl. Genet. vol no. 1 1-34 pages 39-49 (1981) Y N, Leemans et al, J. of Mol. Appl. Genet. vol 1 no. 2 1-34 pages 149-164 (1981) "A" document adming the general state of the art which is not considered to so of particular relevance "E" earlier document building relevance to a or affect the international filing cate "L" document which may implement addition or other special readsh in as specified. "C" document which may implement outs on arrorty claim(s) or affect is establish me contested and of a first he international filing cate "C" document which may implement addition or other special readsh in as specified. "C" document such shed arror to the international filing date but later than the priority cate claimed. "CERTIFICATION Is of the Actual Completion of the International Search." ARCH 14, 1984 "T" later document outlished after the international filing date but later than the priority cate and or after the international filing action to consider the claimed of the consideration of the consider	X N, Otten et al, Mol. Gen. Genet	vol 183 pages 209-213	
Special categories of cited documents: 13 A pages 149-164 (1981) The	Special categories of cited documents: 19 No. Leemans et al., J. of Mol. Appl. Genet. vol 1 no. 2 1–34 Pages 149–164 (1981) The document defining the general state of the art which is not considered to be of paticular relevance The document which may throw counts on priority claim(s) or which the may throw counts on priority cate of another defining cate The document which may throw counts on priority claim(s) or which the state of the priority cate of the priority cate of the priority cate of the priority cate claimed The document politicals relevance in claimed inventional filing date but the priority cate claimed The document politicals relevance in claimed inventional content means The document politicals relevance in claimed inventional filing date but the priority cate claimed The document politicals relevance in claimed inventional filing date but the priority cate claimed The document which counts do not to the international filing date but the priority cate claimed The document which may throw counts on priority claim(s) or which may throw counts on priority cate invention or content politicals relevance in claimed inventional filing date but the priority cate claimed The document which may throw counts on priority claim(s) or which may throw counts on priority claim(s) or which may throw counts on priority cate claimed The document which may throw counts on priority claim(s) or which may throw the priority cate claim or or or or or or	Y N, Otten et al, Mol. Gen. Genet	. vol 183 pages 209-213	
Special categories of cited documents: 19 "A" document adming the general state of the art which is not considered to be apricular relevance. "E" earlier document which may throw doubts on priority claim(s) or Anich is Cited to establish mire published on or after the international filing date. "I" later document published after the international considered to be of particular relevance. "T" later document published after the international considered to be of particular relevance invention. "T" later document published after the international filing date on considered to explore account accounts of the published on critical accounts of the published on critical accounts of the considered provide an invention cannot be considered provide an invention account be considered to reconsidered to reconsidered to reconsidered to reconsidered to reconsidered considered to reconsidered	Special categories of cited documents: 19 "A" document adfining the general state of the art which is not considered to be of particular relevance. "Considered to be of particular relevance if cannot be considered to be of particular relevance. "C" document which may throw doubts on priority claim(s) or which is called to establish the substance of the state of the art which is and cannot be considered moved or cannot be considered to whole an invention and the means. "P" document published prior to the international filing date but later than the priority date claimed. "CERTIFICATION Date of Mailing of this International Search Report to the Actuel Completion of the International Search Report to the Actuel Completion of the International Search Report to the Actuel Completion of the International Search to the International Search Report to the Actuel Completion of the International Search to the International Search Report to the International Search Rep	Y N, Matzke et al, J. of Mol. App	1. Genet. vol no. !	. 1–34
"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing cate. "C" document which may throw doubts on priority claim(s) or which is clied to ustaclish the published of another considered hower of the state to estaclish the published of another of cannot be considered hower or cannot be considered to evolve an inventive state in relevance. The claimed inventor cannot be considered to evolve an inventive state or comment of particular relevance the claimed inventor cannot be considered to evolve an inventive state or comment of particular relevance the claimed inventor cannot be considered to evolve an inventive state or comment of particular relevance the claimed inventor cannot be considered to evolve an inventive state or comment of particular relevance the claimed inventor cannot be considered to evolve an inventive state or comment of particular relevance the claimed cannot be considered to evolve an inventive state or comment of particular relevance the claimed cannot be considered to evolve an inventive state or comment of particular relevance the claimed cannot be considered to evolve an inventive state or comment of particular relevance the claimed cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot	or printly date and not in conflict with the abor cation is considered to be of particular relevance. "E" earlier document but published on or after the international filing date. "L" document which may throw doubts on priority claim(s) or which is clied to establish the bulliation or clied to establish the bulliation date of another cannot be considered novel or cannot be considered to involve an inventive size. "The document referring to an oral disclosure, use, exhibition or other means." "O" document referring to an oral disclosure, use, exhibition or other means." "O" document oublished prior to the international filing date but later than the priority date claimed. "CERTIFICATION. Date of Mailing of this International Search Report in the Actual Completion of the International Search." 2.1 MAR 1984	Y N, Leemans et al, J. of Mol. Ap	pl. Genet. vol I no. 2	: . 1-34
or priority date and not in conflict with the activation but considered to be of particular relevance. "A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filling date. "L" document which may throw doubts on priority claim(s) or which is clied to establish the published priority claim(s) or catallon or other special reason (as specified). "O" document referring to an oral disclosure, use, exhibition or other means. "P" document published priority date claimed. "A" document published prior to the international filling date but later than the priority date claimed. "CERTIFICATION. Date of Mailing of this International Search Report 2.	or printly date and not in conflict with the abor cation is considered to be of particular relevance. "E" earlier document but published on or after the international filing date. "C" document which may throw doubts on priority claim(s) or which is clied to establish the bublished or priority claim(s) or cation or other special reason (as specified). "O" document referring to an oral disclosure, use, exhibition or other means. P" document published prior to the international filing date but later than the priority date claimed. CERTIFICATION. ARCH 14, 1984. Or document seffining the general state of the art which is not considered to income an inventive size. """ document of particular relevance the claimed involve an inventive size. """ document published prior to the international filing date but later than the priority date claimed. """ document member of the same patent family. Date of Mailing of this International Search Report in the Actual Completion of the International Search. 2.1 MAR 1984.			: .
"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing cate. "C" document which may throw doubts on priority claim(s) or which is clied to establish the published of an oral disclosure, use, exhibition or other nears. "O" document referring to an oral disclosure, use, exhibition or other means. "P" document bublished prior to the international filing date but later than the priority cate claimed. "CERTIFICATION. Date of Mailing of this International Search Report and content and in confidency with the activation of the International Search Report and content in confidency in reference the claimed inventive size contents of particular relevance the claimed inventive size contents of particular relevance the claimed inventive size contents of particular relevance the claimed cannot be considered to most or cannot be considered for cannot be considered to most or cannot be considered to considered to most or cannot be considered to most or cannot be considered to considered to most or cannot be considered to most or cannot be considered to considered to most or cannot be considered to cannot be considered to most or cannot or cannot o	"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing date. "L" document which may throw doubts on priority claim(s) or Anich is clied to establish the bullication or other special redson (as specified). "O" document referring to an oral disclosure, use, exhibition or other means. "P" document oublished prior to the international filing date but later than the priority cate claimed. "CERTIFICATION. ARCH 14, 1984.			
"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing cate. "C" document which may throw doubts on priority claim(s) or which is clied to establish the published of an oral disclosure, use, exhibition or other nears. "O" document referring to an oral disclosure, use, exhibition or other means. "P" document bublished prior to the international filing date but later than the priority cate claimed. "CERTIFICATION. Date of Mailing of this International Search Report and content and in confidency with the activation of the International Search Report and content in confidency in reference the claimed inventive size contents of particular relevance the claimed inventive size contents of particular relevance the claimed inventive size contents of particular relevance the claimed cannot be considered to most or cannot be considered for cannot be considered to most or cannot be considered to considered to most or cannot be considered to most or cannot be considered to considered to most or cannot be considered to most or cannot be considered to considered to most or cannot be considered to cannot be considered to most or cannot or cannot o	"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing date. "L" document which may throw doubts on priority claim(s) or Anich is clied to establish the bullication or other special redson (as specified). "O" document referring to an oral disclosure, use, exhibition or other means. "P" document oublished prior to the international filing date but later than the priority cate claimed. "CERTIFICATION. ARCH 14, 1984.			•
"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing cate. "C" document which may throw doubts on priority claim(s) or which is clied to establish the published of an oral disclosure, use, exhibition or other nears. "O" document referring to an oral disclosure, use, exhibition or other means. "P" document bublished prior to the international filing date but later than the priority cate claimed. "CERTIFICATION. Date of Mailing of this International Search Report and content and in confidency with the activation of the International Search Report and content in confidency in reference the claimed inventive size contents of particular relevance the claimed inventive size contents of particular relevance the claimed inventive size contents of particular relevance the claimed cannot be considered to most or cannot be considered for cannot be considered to most or cannot be considered to considered to most or cannot be considered to most or cannot be considered to considered to most or cannot be considered to most or cannot be considered to considered to most or cannot be considered to cannot be considered to most or cannot or cannot o	"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing date. "L" document which may throw doubts on priority claim(s) or Anich is clied to establish the bullication or other special redson (as specified). "O" document referring to an oral disclosure, use, exhibition or other means. "P" document oublished prior to the international filing date but later than the priority cate claimed. "CERTIFICATION. ARCH 14, 1984.			
"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing cate. "C" document which may throw doubts on priority claim(s) or which is clied to ustaclish the published of another considered hower of the state to estaclish the published of another of cannot be considered hower or cannot be considered to evolve an inventive state in relevance. The claimed inventor cannot be considered to evolve an inventive state or comment of particular relevance the claimed inventor cannot be considered to evolve an inventive state or comment of particular relevance the claimed inventor cannot be considered to evolve an inventive state or comment of particular relevance the claimed inventor cannot be considered to evolve an inventive state or comment of particular relevance the claimed inventor cannot be considered to evolve an inventive state or comment of particular relevance the claimed cannot be considered to evolve an inventive state or comment of particular relevance the claimed cannot be considered to evolve an inventive state or comment of particular relevance the claimed cannot be considered to evolve an inventive state or comment of particular relevance the claimed cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot be considered to evolve an inventive state or cannot	or printly date and not in conflict with the abor cation is considered to be of particular relevance. "E" earlier document but published on or after the international filing date. "L" document which may throw doubts on priority claim(s) or which is clied to establish the bulliation or clied to establish the bulliation date of another cannot be considered novel or cannot be considered to involve an inventive size. "The document referring to an oral disclosure, use, exhibition or other means." "O" document referring to an oral disclosure, use, exhibition or other means." "O" document oublished prior to the international filing date but later than the priority date claimed. "CERTIFICATION. Date of Mailing of this International Search Report in the Actual Completion of the International Search." 2.1 MAR 1984			1
"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing cate. "C" document which may throw doubts on priority claim(s) or Anich is clied to establish the published of an oral disclosure, use, exhibition or other means. "O" document referring to an oral disclosure, use, exhibition or other means. "P" document bublished prior to the international filing date but later than the priority cate claimed. "CERTIFICATION. Date of Mailing of this International Search Report is considered. "A" condend reference the claimed inventive size or cannot be considered to inventive size. "O" document priority cate claimed. "A" document published prior to the international filing date but later than the priority cate claimed. "A" document defining the general state of the art which is not criterity at a discretation but invention. "X" cocument of particular relevance the claimed cannot be considered to inventive size. "Y" cocument of particular relevance the claimed cannot be considered to inventive size. "Y" cocument of particular relevance the claimed cannot be considered to inventive size. "Y" cocument of particular relevance the claimed cannot be considered to inventive size. "Y" cocument of particular relevance the claimed cannot be considered to cannot be	"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing date. "L" document which may throw doubts on priority claim(s) or Anich is clied to establish the bublished of another claim(s) or Claim or other special reason the bublished or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive site. "O" document referring to an oral disclosure, use, exhibition or other means. "P" document published prior to the international filing date but later than the priority cate claimed. CERTIFICATION ARCH 14, 1984 Oate of Mailing of this International Search Report in the Actual Completion of the International Search.	İ		
"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing cate. "C" document which may throw doubts on priority claim(s) or which is cited to ustaclish the published of an oral disclosure, use, exhibition or other means. "O" document referring to an oral disclosure, use, exhibition or other means. "P" document bublished prior to the international filing date but later than the priority cate claimed. "CERTIFICATION. Date of Mailing of this International Search Report is considered to the international Search Report is considered to the international Search Report is considered to income an inventive size and not in confidence in the drivention but cannot be considered to understand the crimciple of the actual and not in confidence in the drivention but cannot be considered to consid	or printly date and not in conflict with the abor cation is considered to be of particular relevance. "E" earlier document but published on or after the international filing date. "L" document which may throw doubts on priority claim(s) or which is clied to establish the bulliation or clied to establish the bulliation date of another cannot be considered novel or cannot be considered to involve an inventive size. "The document referring to an oral disclosure, use, exhibition or other means." "O" document referring to an oral disclosure, use, exhibition or other means." "O" document oublished prior to the international filing date but later than the priority date claimed. "CERTIFICATION. Date of Mailing of this International Search Report in the Actual Completion of the International Search." 2.1 MAR 1984	i		•
A" document defining the general state of the art which is not considered to be of particular relevance. E" earlier document but published on or after the international filing date. L" document which may throw doubts on priority claim(s) or which is cited to establish the bublished of another considered novel or cannot be considered to relevance the claimed invention. The document which may throw doubts on priority claim(s) or which is cited to establish the bublished on priority claim(s) or contain or cited to understand the priority relevance the claimed cannot be considered to considered to considered to relevance the claimed concentration of particular relevance the claimed cannot be considered to relevance the claimed concentration of particular relevance the claimed cannot be considered to relevance the claimed to c	A" document defining the general state of the art which is not considered to be of particular relevance. E" earlier document but published on or after the international filing cate. L" document which may throw doubts on priority claim(s) or Anich is cited to estatish the published prior to the international filing date but later than the priority cate claimed. CERTIFICATION ARCH 14, 1984 or priority date and not in conflict with the activation is not cited to understand the priority which the art which is not considered to income a theory underlying to earlied to understand the priority relevance. The claimed inventor cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive size. The document referring to an oral disclosure, use, exhibition or other means. B" document priority cate claimed. CERTIFICATION Date of Mailing of this International Search is 2.1 MAR 1984			
"A" document defining the general state of the art which is not considered to be of particular relevance. "E" earlier document but published on or after the international filing cate. "C" document which may throw doubts on priority claim(s) or which is cited to understand the principle or theory underlying the considered novel or cannot be considered or cannot be considered novel or cannot be considered in relevance. The claimed inventor cannot be considered to moving an inventive size of the comment of particular relevance the claimed inventor cannot be considered to moving an inventive size of the comment of particular relevance the claimed considered to moving an inventive size of the comment of particular relevance the claimed cannot be considered to moving an inventive size of the comment of particular relevance the claimed cannot be considered to moving an inventive size of the comment of particular relevance the claimed cannot be considered to moving the considered to moving the comment of particular relevance the claimed cannot be considered to moving the considered to moving the considered to moving the comment of particular relevance the claimed cannot be considered to an inventive size. "T" codument of particular relevance the claimed cannot be considered to an inventive size of the comment of particular relevance the claimed cannot be considered to moving the considered to moving	or printly date and not in conflict with the abor cation is considered to be of particular relevance. "E" earlier document but published on or after the international filing date. "L" document which may throw doubts on priority claim(s) or which is clied to establish the bulliation or clied to establish the bulliation date of another cannot be considered novel or cannot be considered to involve an inventive size. "The document referring to an oral disclosure, use, exhibition or other means." "O" document referring to an oral disclosure, use, exhibition or other means." "O" document oublished prior to the international filing date but later than the priority date claimed. "CERTIFICATION. Date of Mailing of this International Search Report in the Actual Completion of the International Search." 2.1 MAR 1984	:		
filing cate filing cate Cumument which may throw doubts on priority claim(s) or which is clied to establish the but published on priority claim(s) or which is clied to establish the but published of priority claim(s) or which is clied to establish the but published of priority claim(s) or children special reason (as specified) Comment referring to an oral disclosure, use, exhibition or other means P''' document bublished prior to the international filing date but later than the priority cate claimed CERTIFICATION Date of Mailing of this International Search Report x	"X" occument but published on or after the international filing date filing da	'A" document defining the general state of the art which is not	or energy date and not in certification to certificate to understand the principal	ct with the appropriation bu
Arien is edited to establish the publication date of another citation or other special reason (as specified) Of document referring to an oral disclosure, use, exhibition or other means. P" document published prior to the international filing date but later than the priority cate claimed CERTIFICATION To comment of particular relevance, the claimed invention of cannot be considered to involve an inventive step when the comments is combination being obvious to a person skille in the art document member of the same patent family. CERTIFICATION To comment of particular relevance, the claimed inventive step when the comments of particular relevance, the claimed inventive step when the comments of priority and person skille in the art document member of the same patent family. CERTIFICATION To comment of particular relevance, the claimed inventive step when the comments of person skille in the art. The comment of particular relevance the claimed inventive step when the comments of person skille in the art. The comment of particular relevance the claimed inventive step when the comments of person skille in the art. The comment of particular relevance the claimed inventive step when the comments of person skille in the art. The comment of particular relevance the claimed inventive step when the comments of person skille in the art. The comment of particular relevance the claimed inventive step when the comments of person skille in the art. The comment of particular relevance the claimed invention of person skille in the art. The comment of particular relevance the claimed in the comment of person skille in the art. The comment of particular relevance the claimed in the comment of person skille and person skille in the art. The comment of particular relevance the claimed in the comment of person skille and pe	cocument of particular relevance the claimed inventor of cannot be considered to involve an inventor such considered to involve and inventor such considered to involve and inventor such considered to involve and inventor such considered to involve an inventor such considered to inventor such consider	'E" earier document but published on or after the international filing cate	"X" document of particular relevan- cannot be considered novel or	cer the claimed invention cannot be considered t
P" document published prior to the international filing date but later than the priority cate claimed "4" document member of the same patent family CERTIFICATION to of the Actual Completion of the International Search 1 Date of Mailing of this International Search Report 1	P" document published prior to the international filing date but later than the priority date claimed "4" document member of the same patent family CERTIFICATION to of the Actual Completion of the International Search: ARCH 14, 1984 Date of Mailing of this International Search Report 1 2 1 MAR 1984	Affice is citied to establish the publication date of another citation or other special reason (as specified). Of document referring to an oral disclosure, use, exhibition or	TY" document of particular relevant cannot be considered to involve document of campings with one	an mare other such cocu
to of the Actual Completion of the International Search : Date of Mailing of this International Search Report :	ARCH 14, 1984 Date of Mailing of this International Search 1 2 1 MAR 1984	P" document published prior to the international filing date but	in the art	
	ARCH 14, 1984 2 1 MAR 1984			Penna 7
· · · · · · · · · · · · · · · · · · ·				